: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Flying Publisher

COVID-19: Daily Top 10 Papers

Hepatitis

Free Subscription

Articles published in J Viral Hepat
Retrieve available abstracts of 734 articles:
HTML format

Single Articles

July 2021

KAMAL H, Fornes R, Simin J, Stal P, et al
Risk of Hepatocellular Carcinoma in Hepatitis B and D Virus Co-Infected Patients: A Systematic Review and Meta-analysis of Longitudinal studies.
J Viral Hepat. 2021 Jul 22. doi: 10.1111/jvh.13577.
PubMed Abstract available

BISCHOFF J, Mauss S, Lutz T, Cordes C, et al
Late presentation of chronic hepatitis C patients in the era of direct acting antivirals - Data from the German Hepatitis C-Registry.
J Viral Hepat. 2021 Jul 21. doi: 10.1111/jvh.13576.
PubMed Abstract available

BARDSLEY M, Heinsbroek E, Harris R, Croxford S, et al
The Impact Of Direct-Acting Antivirals On Hepatitis C Viraemia Among People Who Inject Drugs In England; Real-World Data 2011-2018.
J Viral Hepat. 2021 Jul 16. doi: 10.1111/jvh.13575.
PubMed Abstract available

NA JE, Sinn DH, Lee JH, Jang HJ, et al
Efficacy of entecavir vs tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response.
J Viral Hepat. 2021 Jul 12. doi: 10.1111/jvh.13572.
PubMed Abstract available

VARCHETTA S, Mele D, D'Ambrosio R, Perbellini R, et al
A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C.
J Viral Hepat. 2021 Jul 6. doi: 10.1111/jvh.13570.
PubMed Abstract available

LI J, Qu L, Sun X, Liu Y, et al
Peg-interferon alpha add-on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg positive chronic hepatitis B naive patients.
J Viral Hepat. 2021 Jul 6. doi: 10.1111/jvh.13571.
PubMed Abstract available

ERICE A, Varillas-Delgado D, Caballero C
Prevalence and characteristics of hepatitis C virus infection detected by extended screening of working-age adults in Madrid (Spain).
J Viral Hepat. 2021 Jul 5. doi: 10.1111/jvh.13564.
PubMed Abstract available

KAMALAPIRAT T, Ungtrakul T
Reply to "Consider more about risk scores for predicting hepatocellular carcinoma in patients with chronic hepatitis B".
J Viral Hepat. 2021 Jul 5. doi: 10.1111/jvh.13566.
PubMed Abstract available

LOU T, Li B, Xiong P, Jin C, et al
External Validation of Hepatocellular Carcinoma Risk Scores in Patients with Chronic Hepatitis B Virus Infection in China.
J Viral Hepat. 2021 Jul 4. doi: 10.1111/jvh.13569.
PubMed Abstract available

FARSIMADAN M, Riahi SM, Muhammad HM, Emamvirdizadeh A, et al
The Effects of Hepatitis B Virus Infection on Natural and IVF Pregnancy: A Meta-analysis Study.
J Viral Hepat. 2021 Jul 3. doi: 10.1111/jvh.13565.
PubMed Abstract available

LIU Y
Consider more about risk scores for predicting hepatocellular carcinoma in patients with chronic hepatitis B.
J Viral Hepat. 2021 Jul 3. doi: 10.1111/jvh.13568.
PubMed Abstract available

LIU Y
Reply to "Consider more about risk scores for predicting hepatocellular carcinoma in patients with chronic hepatitis B" - a reply.
J Viral Hepat. 2021 Jul 3. doi: 10.1111/jvh.13567.
PubMed Abstract available

June 2021

GIRALDEZ-GALLEGO A, Rodriguez-Seguel E, Pascasio-Acevedo JM
Optimal hepatitis B vaccination schedule for cirrhotic patients: a still unanswered question.
J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13563.
PubMed Abstract available

KIM HP, Edwards A, Reeve BB, Golin CE, et al
Symptoms and Functioning Improve after Chronic Hepatitis C Cure as Assessed by the Memorial Symptom Assessment Scale and PROMIS Measures.
J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13561.
PubMed Abstract available

KUMADA T, Toyoda H, Yasuda S, Tada T, et al
Long-term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis.
J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13562.
PubMed Abstract available

YOO S, Lim TS, Lee HW, Kim JK, et al
Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B.
J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13560.
PubMed Abstract available

KANG Q, Xu J, Luo H, Tan N, et al
Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication.
J Viral Hepat. 2021 Jun 9. doi: 10.1111/jvh.13558.
PubMed Abstract available

NISHIDA Y, Imamura M, Yuji T, Morio K, et al
Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients.
J Viral Hepat. 2021 Jun 9. doi: 10.1111/jvh.13557.
PubMed Abstract available

May 2021

WANG S, Fang S, Liu Y
The 5-year cumulative incidence HCC development and treatment regimen in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment.
J Viral Hepat. 2021 May 29. doi: 10.1111/jvh.13553.
PubMed Abstract available

BROWN C, Siegele M, Wright M, Cook C, et al
Injecting network structure determines the most efficient strategy to achieve Hepatitis C elimination in people who inject drugs.
J Viral Hepat. 2021 May 28. doi: 10.1111/jvh.13554.
PubMed Abstract available

RODRIGUEZ-TAJES S, Lens S, Forns X
Reply to: Optimal hepatitis B vaccination schedule for cirrhotic patients: a still unanswered question.
J Viral Hepat. 2021 May 28. doi: 10.1111/jvh.13555.
PubMed Abstract available

ARSLAN F, Franci G, Nastri BM, Pagliano P, et al
Hepatitis B virus-induced Hepatocarcinogenesis: A Virological and Oncological Perspective.
J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13551.
PubMed Abstract available

SMITH DA, Bradshaw D, Mbisa J, Manso CF, et al
Real World SOF/VEL/VOX Retreatment Outcomes and Viral Resistance Analysis for HCV Patients with Prior Failure to DAA Therapy.
J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13549.
PubMed Abstract available

OHLENDORF V, Schafer A, Christensen S, Heyne R, et al
Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting- results from the German Hepatitis C-Registry (DHC-R).
J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13546.
PubMed Abstract available

DUFFELL E, Cortez-Pinto H, Simonova M, Dalgard O, et al
Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C.
J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13545.
PubMed Abstract available

LIU PC, Chan C, Huang YH, Chen YJ, et al
Genetic Variants Associated With Serum Alanine Aminotransferase Levels Among Patients With Hepatitis C Virus Infection: A Genome-Wide Association Study.
J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13550.
PubMed Abstract available

KIM S, Powell J, Naugle J, Ricco M, et al
Patient-Reported Experiences with Direct Acting Antiviral Therapy in an Integrated Model of Hepatitis C Care in Homeless Shelters.
J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13544.
PubMed Abstract available

NANA J, Skaare K, Bosson JL, Leroy V, et al
EASL-ALEH 2015 algorithm for the use of transient elastography in treatment-naive patients with Hepatitis B: an independent validation.
J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13548.
PubMed Abstract available

MCDONALD SA, Barclay ST, Innes HA, Fraser A, et al
Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality.
J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13543.
PubMed Abstract available

COMBET C, Bhardwaj N, Hedskog C, Podlaha O, et al
Hepatitis B Virus Genome Diversity in Adolescents: Tenofovir Disoproxil Fumarate Treatment Effect and HBeAg Seroconversion.
J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13547.
PubMed Abstract available

HUANG PY, Wang JH, Hung CH, Lu SN, et al
The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients.
J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13528.
PubMed Abstract available

WOLF JM, Pereira VRZB, Simon D, Lunge VR, et al
Temporal and geographic spreading of hepatitis B virus genotype A (HBV-A) in Brazil and the Americas.
J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13527.
PubMed Abstract available

COWAN E, Hardardt J, Brandspiegel S, Eiting E, et al
Care cascade of patients with Hepatitis C and HIV identified by Emergency Department screening.
J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13529.
PubMed Abstract available

LEE J, Kim GA, Kim HJ, Cho S, et al
Tenofovir Disoproxil Fumarate on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Failure to Preceding Treatments: A Nationwide Cohort Study.
J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13530.
PubMed Abstract available

April 2021

KUMADA T
Reply to: 'Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis'.
J Viral Hepat. 2021 Apr 28. doi: 10.1111/jvh.13514.
PubMed

CHEN H, Ding X, Liao G, Xia M, et al
Hepatitis B surface antigen kinetics after discontinuation of and retreatment with oral antivirals in non-cirrhotic HBeAg-positive chronic hepatitis B.
J Viral Hepat. 2021 Apr 26. doi: 10.1111/jvh.13526.
PubMed Abstract available

CALVARUSO V, Petta S, Cacciola I, Cabibbo G, et al
Liver and Cardiovascular Mortality After Hepatitis C Virus Eradication by DAA: data from RESIST-HCV Cohort.
J Viral Hepat. 2021 Apr 25. doi: 10.1111/jvh.13523.
PubMed Abstract available

FIMMEL CJ, Khan MQ, Belopolsky Y, Imas P, et al
Sustained and cumulative impact of an electronic medical record-based alert on a hepatitis C birth cohort screening program.
J Viral Hepat. 2021 Apr 25. doi: 10.1111/jvh.13524.
PubMed Abstract available

HERNANDEZ C, Trujillo D, Turner CM, Sicro S, et al
Reaching trans-women in San Francisco for efforts to eliminate hepatitis C.
J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13521.
PubMed Abstract available

YU W, Ji H, Long F, Chen S, et al
Inhibition of Hepatitis E Virus Replication by Zinc-Finger Antiviral Protein synergizes with IFN-beta.
J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13522.
PubMed Abstract available

ANUGWOM C, Campbell C, Debes JD
Assessment of subclinical effects of Hepatitis E virus infection in the United States.
J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13519.
PubMed Abstract available

COOPER SL, King WC, Mogul DB, Ghany MG, et al
Clinical Significance of Quantitative e Antigen in a Cohort of Hepatitis B Virus Infected Children and Adults in North America.
J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13520.
PubMed Abstract available

MOKAYA J, Vasylyeva TI, Barnes E, Ansari MA, et al
Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations.
J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13525.
PubMed Abstract available

GOUTZAMANIS S, Spelman T, Harney B, Dietze P, et al
Patient-reported outcomes of the Treatment and Prevention Study: A real-world community-based trial of direct-acting antivirals for hepatitis C among people who inject drugs.
J Viral Hepat. 2021 Apr 20. doi: 10.1111/jvh.13516.
PubMed Abstract available

KAMALAPIRAT T, Yingcharoen K, Ungtrakul T, Soonklang K, et al
Assessing Risk Scores for Predicting Hepatocellular Carcinoma in Thai Patients with Chronic Hepatitis B.
J Viral Hepat. 2021 Apr 20. doi: 10.1111/jvh.13517.
PubMed Abstract available

SHEN DT, Han PC, Ji DZ, Chen HY, et al
Epidemiology estimates of hepatitis D in individuals co-infected with HIV and HBV, 2002-2018: a systematic review and meta-analysis.
J Viral Hepat. 2021 Apr 20. doi: 10.1111/jvh.13512.
PubMed Abstract available

HARTARD C, Fenaux H, Gentilhomme A, Murray JM, et al
Variability in molecular characteristics of Hepatitis E Virus quasispecies could modify viral surface properties and transmission.
J Viral Hepat. 2021 Apr 20. doi: 10.1111/jvh.13513.
PubMed Abstract available

WENG F
Comment on "Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis".
J Viral Hepat. 2021 Apr 19. doi: 10.1111/jvh.13515.
PubMed Abstract available

DZINGIRAI B, Katsidzira L, Matyanga CMJ, Postma MJ, et al
Progress on the elimination of viral hepatitis in Zimbabwe: A review of the policies, strategies and challenges.
J Viral Hepat. 2021 Apr 2. doi: 10.1111/jvh.13510.
PubMed Abstract available

YAO K, Liu J, Wang J, Yan X, et al
Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the gray zone.
J Viral Hepat. 2021 Apr 2. doi: 10.1111/jvh.13511.
PubMed Abstract available

March 2021

RODRIGUEZ-TAJES S, Pocurull A, Lens S, Marino Z, et al
Efficacy of an accelerated double dose Hepatitis B vaccine regimen in patients with cirrhosis.
J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13509.
PubMed Abstract available

BUTT AA, Yan P
Natural History of Hepatitis C Virus Infection in a Large National Seroconversion Cohort in the Direct Acting Antiviral Agent Era: Results from ERCHIVES.
J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13507.
PubMed Abstract available

SAMALA N, Abdallah W, Poole A, Shamseddeen H, et al
Insight Into The Acute hepatitis A Outbreak In Indiana.
J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13504.
PubMed Abstract available

JI JH, Park SY, Son WJ, Shin HJ, et al
External validation of CAGE-B and SAGE-B scores for Asian chronic hepatitis B patients with well-controlled viremia by antivirals.
J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13506.
PubMed Abstract available

LIU CH, Sun HY, Hsieh SM, Liu WC, et al
Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct acting antivirals and antiretroviral therapy.
J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13502.
PubMed Abstract available

BAIANO CX, Caven M, Robinson EM, Dillon JF, et al
Evaluating and communicating hepatitis C cascades of care data in Tayside, Scotland: A journey towards elimination.
J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13505.
PubMed Abstract available

MACGREGOR L, Ward Z, Martin NK, Nicholls J, et al
The cost-effectiveness of case-finding strategies for achieving hepatitis C elimination among men who have sex with men in the UK.
J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13503.
PubMed Abstract available

POST G, Howell J, Sow A, Ndow G, et al
Clinical utility of quantifying hepatitis B surface antigen in African patients with chronic hepatitis B.
J Viral Hepat. 2021 Mar 22. doi: 10.1111/jvh.13499.
PubMed Abstract available

FARAG MS, Fung S, Tam E, Doucette K, et al
Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study.
J Viral Hepat. 2021 Mar 22. doi: 10.1111/jvh.13500.
PubMed Abstract available

MACIAS J, Tellez F, de Los Santos I, Morano LE, et al
Impact of recent drug use on the efficacy of Elbasvir/Grazoprevir for HCV-infected people on opioid agonist therapy.
J Viral Hepat. 2021 Mar 15. doi: 10.1111/jvh.13496.
PubMed Abstract available

JIANG JJ, Shiels MS, O'Brien TR
Death Certificates Compared to SEER-Medicare Data for Surveillance of Liver Cancer Mortality Due to Hepatitis B or Hepatitis C Infection.
J Viral Hepat. 2021 Mar 15. doi: 10.1111/jvh.13498.
PubMed Abstract available

DOLMAN GE, Koffas A, Phipps E, Kennedy PTF, et al
Clinical and occupational health management of healthcare workers living with chronic hepatitis B: UK policy and international comparisons.
J Viral Hepat. 2021 Mar 4. doi: 10.1111/jvh.13494.
PubMed Abstract available

XIAO Y, Wallace J, Thompson A, Hellard M, et al
A qualitative exploration of enablers for hepatitis B clinical management among ethnic Chinese in Australia.
J Viral Hepat. 2021 Mar 4. doi: 10.1111/jvh.13495.
PubMed Abstract available

February 2021

BAR N, Levy S, Deutsch L, Leshno M, et al
Hepatitis C related cognitive impairment: impact of viral and host factors and response to therapy.
J Viral Hepat. 2021 Feb 23. doi: 10.1111/jvh.13492.
PubMed Abstract available

BANDERA A, Lorenzini P, Taramasso L, Cozzi-Lepri A, et al
The impact of DAA-mediated HCV eradication on CD4(+) and CD8(+) T lymphocyte trajectories in HIV/HCV coinfected patients: data from the ICONA Foundation Cohort.
J Viral Hepat. 2021 Feb 18. doi: 10.1111/jvh.13488.
PubMed Abstract available

VEGAS JJ, Flores-Herrera J, Latasa P, Garrido-Estepa M, et al
Reduction in hepatitis C-related hospitalisations after the implementation of the Strategic Plan for Tackling Hepatitis C in the Spanish National Health System: regional level differences.
J Viral Hepat. 2021 Feb 18. doi: 10.1111/jvh.13491.
PubMed Abstract available

SHIMAKAWA Y, Vernoux L, Gabassi A, Mercier-Delarue S, et al
Analytical validation of hepatitis B core-related antigen (HBcrAg) using dried blood spots (DBS).
J Viral Hepat. 2021 Feb 17. doi: 10.1111/jvh.13489.
PubMed Abstract available

HARNEY BL, Brereton R, Whitton B, Pietrzak D, et al
Hepatitis C treatment in a co-located mental health and alcohol and drug service using a nurse-led model of care.
J Viral Hepat. 2021 Feb 17. doi: 10.1111/jvh.13487.
PubMed Abstract available

TOKUCHI Y, Suda G, Kimura M, Maehara O, et al
Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass.
J Viral Hepat. 2021 Feb 15. doi: 10.1111/jvh.13484.
PubMed Abstract available

FRAZZONI L, Sikandar U, Mazzella G, Fuccio L, et al
A multimedia multilanguage web-based platform can assess and increase the awareness on HCV infection of Pakistani people living in Italy.
J Viral Hepat. 2021 Feb 15. doi: 10.1111/jvh.13486.
PubMed Abstract available

GUZELBULUT F, Gokcen P, Can G, Adali G, et al
Validation of the HCC-RESCUE Score to Predict Hepatocellular Carcinoma Risk in Caucasian Chronic Hepatitis B Patients Under Entecavir or Tenofovir Therapy.
J Viral Hepat. 2021 Feb 15. doi: 10.1111/jvh.13485.
PubMed Abstract available

SAHAKYAN Y, Lee-Kim V, Bremner KE, Bielecki JM, et al
Impact of direct acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis C: systematic review and meta-analysis.
J Viral Hepat. 2021 Feb 8. doi: 10.1111/jvh.13482.
PubMed Abstract available

VERGARA M, Miquel M, Vela E, Cleries M, et al
Use of healthcare resources and drug expenditure before and after treatment of chronic hepatitis C with direct antiviral agents.
J Viral Hepat. 2021 Feb 8. doi: 10.1111/jvh.13479.
PubMed Abstract available

TUNG CH, Li CY, Chen YC, Chen YC, et al
Association between nucleos(t)ide analogue therapy for hepatitis B and Sjogren's syndrome: 15-year analysis of the national database of Taiwan.
J Viral Hepat. 2021 Feb 6. doi: 10.1111/jvh.13481.
PubMed Abstract available

KREKULOVA L, Honzak R, Riley LW
Viral hepatitis C pandemic: challenges and threats to its elimination.
J Viral Hepat. 2021 Feb 6. doi: 10.1111/jvh.13480.
PubMed Abstract available

WEI YJ, Hsu PY, Lee JJ, Niu SW, et al
Evolutionary seroepidemiology of viral hepatitis and the gap in hepatitis C care cascades among uremic patients receiving hemodialysis in Taiwan- the FORMOSA-LIKE group.
J Viral Hepat. 2021 Feb 3. doi: 10.1111/jvh.13477.
PubMed Abstract available

PRITCHARD H, Hwang JP, Angelidakis G, Yibirin M, et al
Hepatitis B Virus Reactivation in Cancer Patients Receiving Direct-Acting Antivirals for Hepatitis C Virus Infection.
J Viral Hepat. 2021 Feb 1. doi: 10.1111/jvh.13478.
PubMed Abstract available

January 2021

KIRINO S, Tamaki N, Kurosaki M, Inada K, et al
Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment.
J Viral Hepat. 2021 Jan 23. doi: 10.1111/jvh.13473.
PubMed Abstract available

WANG SQ, Shen Y, Li J, Liu Y, et al
Entecavir-induced Interferon-lambda1 suppresses type 2 innate lymphoid Cells in Patients with Hepatitis B virus-related liver cirrhosis.
J Viral Hepat. 2021 Jan 22. doi: 10.1111/jvh.13476.
PubMed Abstract available

LOCKART I, Hajarizadeh B, Alavi M, Davison S, et al
Title: Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival.
J Viral Hepat. 2021 Jan 22. doi: 10.1111/jvh.13475.
PubMed Abstract available

WILDER JM, Evon DM, Jean Proeschold-Bell R, Yao J, et al
Why do patients with chronic hepatitis C drink alcohol? An examination of pain, depression, and drinking motives.
J Viral Hepat. 2021 Jan 21. doi: 10.1111/jvh.13474.
PubMed Abstract available

SONG A, Xiaoxiao W, Lu J, Jin Y, et al
Durability of Hepatitis B Surface Antigen seroclearance and subsequent Risk for hepatocellular Carcinoma : a meta-analysis.
J Viral Hepat. 2021 Jan 17. doi: 10.1111/jvh.13471.
PubMed Abstract available

XIONG Y, Liu C, Huang S, Wang J, et al
Impact of maternal infection with hepatitis B virus on pregnancy complications and neonatal outcomes for women undergoing assisted reproductive technology treatment: a population-based study.
J Viral Hepat. 2021 Jan 16. doi: 10.1111/jvh.13472.
PubMed Abstract available

SU X, Zhao X, Deng JL, Li SN, et al
Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes: A systematic review and meta-analysis.
J Viral Hepat. 2021 Jan 16. doi: 10.1111/jvh.13469.
PubMed Abstract available

CHEN B, Ma ZH, Xu B, Chang H, et al
Evaluation of seven Rapid Diagnostic Tests for Detection of Hepatitis C Virus Antibodies in China.
J Viral Hepat. 2021 Jan 9. doi: 10.1111/jvh.13466.
PubMed Abstract available

SHUMBUSHO F, Liu AF, Kateera F, Kabahizi J, et al
Risk factors for difficult-to-treat Hepatitis C Virus genotype 4r in Rwanda and implications for elimination in sub-Saharan africa.
J Viral Hepat. 2021 Jan 9. doi: 10.1111/jvh.13467.
PubMed Abstract available

FRANCESCA ROMANA P, Francesco S, Massimo S, Antonio Giulio B, et al
Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care center: results of the Telepass project.
J Viral Hepat. 2021 Jan 9. doi: 10.1111/jvh.13465.
PubMed Abstract available

December 2020

MOHAREB AM, Kouame GM, Gabassi A, Gabillard D, et al
Mortality in relation to hepatitis B virus (hbv) infection status among hiv-hbv co-infected patients in sub-Saharan Africa after immediate initiation of antiretroviral therapy.
J Viral Hepat. 2020 Dec 31. doi: 10.1111/jvh.13461.
PubMed Abstract available

KUSHNER T, Kaplowitz E, Mei R, Xu C, et al
Adherence to pregnancy hepatitis B care guidelines in women and infants in the and evaluation of two interventions to improve care: a multi-center hospital-based study.
J Viral Hepat. 2020 Dec 29. doi: 10.1111/jvh.13459.
PubMed Abstract available

O'GORMAN P, Strahan O, Ferguson D, Monaghan A, et al
Improvement in cognitive impairment following a 12-week aerobic exercise intervention in individuals with non-cirrhotic chronic hepatitis C.
J Viral Hepat. 2020 Dec 28. doi: 10.1111/jvh.13460.
PubMed Abstract available

KUMADA T, Toyoda H, Yasuda S, Miyake N, et al
Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis.
J Viral Hepat. 2020 Dec 11. doi: 10.1111/jvh.13457.
PubMed Abstract available

COOPER C, Driedger M, Wong D, Haylock-Jacobs S, et al
Distinct Hepatitis B and HIV co-infected populations in Canada.
J Viral Hepat. 2020 Dec 11. doi: 10.1111/jvh.13453.
PubMed Abstract available

FABBIANI M, Lombardi A, Colaneri M, Del Poggio P, et al
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting.
J Viral Hepat. 2020 Dec 11. doi: 10.1111/jvh.13454.
PubMed Abstract available

WASUWANICH P, Ingviya T, Thawillarp S, Teshale EH, et al
Hepatitis E-Associated Hospitalizations in the United States: 2010-2015 and 2015-2017.
J Viral Hepat. 2020 Dec 11. doi: 10.1111/jvh.13458.
PubMed Abstract available

YOUNOSSI ZM, Stepanova M, Younossi I, Racila A, et al
Development and validation of a hepatitis B-specific health-related quality of life instrument: CLDQ-HBV.
J Viral Hepat. 2020 Dec 11. doi: 10.1111/jvh.13451.
PubMed Abstract available

CHANG JW, Kim SU
Authors' response: Additional more factors should be included in predicting risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
J Viral Hepat. 2020 Dec 11. doi: 10.1111/jvh.13450.
PubMed Abstract available

CAMPBELL C, Wang T, McNaughton AL, Barnes E, et al
Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis.
J Viral Hepat. 2020 Dec 10. doi: 10.1111/jvh.13452.
PubMed Abstract available

GORRIS M, van der Lecq BM, van Erpecum KJ, de Bruijne J, et al
Treatment for Chronic Hepatitis E Virus Infection: A Systematic Review and Meta-analysis.
J Viral Hepat. 2020 Dec 10. doi: 10.1111/jvh.13456.
PubMed Abstract available

PENG CW, Jeng WJ, Chien RN, Liaw YF, et al
The impact of hepatitis flare on HBeAg loss was effective mainly in the first year of Nucleot(s)ide therapy in chronic hepatitis B.
J Viral Hepat. 2020 Dec 3. doi: 10.1111/jvh.13449.
PubMed Abstract available

LIU Y, Mo Y, Wu A
Additional more factors should be included in predicting risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
J Viral Hepat. 2020 Dec 2. doi: 10.1111/jvh.13448.
PubMed Abstract available

PAPATHEODORIDI A, Chatzigeorgiou A, Chrysavgis L, Lembessis P, et al
Circulating cell-free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients.
J Viral Hepat. 2020 Dec 1. doi: 10.1111/jvh.13446.
PubMed Abstract available

CHAN K, Elsum I, Gold J, Layton C, et al
Increasing hepatitis C testing and linkage to care: Results of a testing campaign with incentives at primary care clinics in Melbourne, Australia.
J Viral Hepat. 2020 Dec 1. doi: 10.1111/jvh.13447.
PubMed Abstract available

CHEN L, Huang S, Yang J, Cheng X, et al
Clinical characteristics in patients with SARS-CoV-2/HBV co-infection.
J Viral Hepat. 2020;27:1504-1507.
PubMed Abstract available

November 2020

TADA T, Toyoda H, Kumada T, Kurisu A, et al
Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis.
J Viral Hepat. 2020 Nov 20. doi: 10.1111/jvh.13444.
PubMed Abstract available

WHITELEY D, Speakman E, Elliott L, Davidson K, et al
Provider-related barriers and enablers to the provision of hepatitis C treatment by General Practitioners in Scotland: A behaviour change analysis.
J Viral Hepat. 2020 Nov 20. doi: 10.1111/jvh.13443.
PubMed Abstract available

RAZAVI H
The cost effectiveness of hepatitis C virus elimination in low and middle-income countries.
J Viral Hepat. 2020 Nov 17. doi: 10.1111/jvh.13442.
PubMed Abstract available

YUJI T, Imamura M, Uchida T, Ohya K, et al
Abatacept treatment for patients with severe acute hepatitis caused by hepatitis B virus infection - Pilot study.
J Viral Hepat. 2020 Nov 16. doi: 10.1111/jvh.13441.
PubMed Abstract available

ANASTASIOU OE, Yurdaydin C, Maasoumy B, Hardtke S, et al
A transient early HBV DNA increase during PEG-IFNalpha therapy of hepatitis D indicates loss of infected cells and is associated with HDV RNA and HBsAg reduction.
J Viral Hepat. 2020 Nov 13. doi: 10.1111/jvh.13439.
PubMed Abstract available

WEINHEIMER-HAUS EM, Yu X, Singal AG, Naylor KB, et al
Utilizing public health data to geotarget hepatitis C virus elimination approaches in urban and rural Michigan.
J Viral Hepat. 2020 Nov 13. doi: 10.1111/jvh.13438.
PubMed Abstract available

KIM D, Alshuwaykh OS, Cholankeril G, Wong RJ, et al
Trends in Mortality in Hepatitis C Infection and Alcoholic Liver Disease based on Drug Overdose in the United States.
J Viral Hepat. 2020 Nov 4. doi: 10.1111/jvh.13435.
PubMed Abstract available

RIDRUEJO E, Pinero F, Mendizabal M, Silva M, et al
Direct-Acting Antivirals Treatment Failure in Genotype 2 Hepatitis C chronic Infection.
J Viral Hepat. 2020 Nov 4. doi: 10.1111/jvh.13433.
PubMed Abstract available

KAPADIA SN, Katzman C, Fong C, Eckhardt BJ, et al
Hepatitis C Testing and Treatment Uptake among Young People who Use Opioids in New York City: A Cross-Sectional Study.
J Viral Hepat. 2020 Nov 3. doi: 10.1111/jvh.13437.
PubMed Abstract available

WU D, Hu S, Chen G, Jiao C, et al
Association of Hepatitis C Infection and Risk of Kidney Cancer: A Systematic Review and Meta-analysis of Observational Studies.
J Viral Hepat. 2020 Nov 3. doi: 10.1111/jvh.13434.
PubMed Abstract available

SHEU MJ, Liang FW, Lu TH
Hepatitis C virus infection mortality trends according to three definitions with special concern for the baby boomer birth cohort.
J Viral Hepat. 2020 Nov 3. doi: 10.1111/jvh.13436.
PubMed Abstract available

MULDER MB, de Man RA, Kamar N, Durmaz G, et al
Determining the therapeutic range for ribavirin in transplant recipients with chronic hepatitis e virus infection.
J Viral Hepat. 2020 Nov 1. doi: 10.1111/jvh.13432.
PubMed Abstract available

October 2020

GALLACHER J, McPherson S
Progress towards micro-elimination of hepatitis C in the custodial setting.
J Viral Hepat. 2020 Oct 31. doi: 10.1111/jvh.13428.
PubMed

FAHNOE U, Pedersen MS, Solund C, Ernst A, et al
Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome.
J Viral Hepat. 2020 Oct 31. doi: 10.1111/jvh.13430.
PubMed Abstract available

GOYAL A, Perelson AS, Kandathil AJ, Quinn J, et al
HIV influences clustering and intracellular replication of hepatitis C virus.
J Viral Hepat. 2020 Oct 30. doi: 10.1111/jvh.13429.
PubMed Abstract available

WOLF JM, De Carli S, Pereira VRZB, Simon D, et al
Temporal evolution and global spread of hepatitis B virus genotype G.
J Viral Hepat. 2020 Oct 30. doi: 10.1111/jvh.13431.
PubMed Abstract available

IBRAHIM ES, Abdel-Samiee M, Youssef MI, El-Shazly H, et al
Variceal Recurrence 4 Years post Endoscopic Band Ligation in Hepatitis C Patients who Achieved Sustained Virological Response with Oral Direct Acting Antiviral Therapy.
J Viral Hepat. 2020 Oct 23. doi: 10.1111/jvh.13426.
PubMed Abstract available

REYES-URUENA J, Celly A, Moreno S, Majo X, et al
Hepatitis C virus: testing rate and attrition at linkage to specialized care, Catalonia, Spain 2011-2016.
J Viral Hepat. 2020 Oct 23. doi: 10.1111/jvh.13427.
PubMed Abstract available

ANKCORN M, Said B, Morgan D, Elsharkawy AM, et al
Persistent Hepatitis E virus infection across England and Wales 2009-2017: Demography, virology and outcomes.
J Viral Hepat. 2020 Oct 18. doi: 10.1111/jvh.13424.
PubMed Abstract available

CHAN J, Kim JJ, Barrett BK, Hamadeh A, et al
Cost-Effectiveness Analysis of Sofosbuvir and Velpatasvir in Chronic Hepatitis C Patients with Decompensated Cirrhosis.
J Viral Hepat. 2020 Oct 16. doi: 10.1111/jvh.13419.
PubMed Abstract available

LAURSEN TL, Villesen IF, Leeming DJ, Karsdal MA, et al
Altered balance between collagen formation and degradation after successful direct-acting antiviral therapy of chronic hepatitis C.
J Viral Hepat. 2020 Oct 15. doi: 10.1111/jvh.13416.
PubMed Abstract available

MAFIRAKUREVA N, Lim AG, Khalid GG, Aslam K, et al
Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan.
J Viral Hepat. 2020 Oct 14. doi: 10.1111/jvh.13422.
PubMed Abstract available

LEE J, Cho S, Kim HJ, Lee H, et al
High Level of Medication Adherence Is Required to Lower Mortality in Patients with Chronic Hepatitis B Taking Entecavir: A Nationwide Cohort Study.
J Viral Hepat. 2020 Oct 13. doi: 10.1111/jvh.13418.
PubMed Abstract available

RAFIQUE S, Zahid S, Ali A, Tariq M, et al
Genome wide methylation profiling of HCV pathogenesis to develop diabetes and diabetic complications.
J Viral Hepat. 2020 Oct 13. doi: 10.1111/jvh.13417.
PubMed Abstract available

CHOTIYAPUTTA W, Poosanasuwansri K, Kiattisunthorn K, Chainuvati S, et al
Comparison of viral control between two tenofovir dose reduction regimens (300 mg every 48 hours versus 300 mg every 72 hours) in chronic hepatitis B patients with moderate renal impairment from tenofovir-induced renal dysfunction.
J Viral Hepat. 2020 Oct 12. doi: 10.1111/jvh.13420.
PubMed Abstract available

POOLA S, Sanaka S, Sewell K, Tillmann HL, et al
Hepatitis B Surface Antibody Titers and Hepatitis B Reactivation with Direct-Acting Antiviral Therapy for Hepatitis C.
J Viral Hepat. 2020 Oct 12. doi: 10.1111/jvh.13421.
PubMed Abstract available

CHANG JW, Lee JS, Lee HW, Kim BK, et al
Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir.
J Viral Hepat. 2020 Oct 7. doi: 10.1111/jvh.13411.
PubMed Abstract available

September 2020

KOC OM, Kuypers D, Dupont LJ, Vos R, et al
The effect of universal infant vaccination on the prevalence of hepatitis B immunity in adult solid organ transplant candidates.
J Viral Hepat. 2020 Sep 28. doi: 10.1111/jvh.13414.
PubMed Abstract available

RAZAVI H, Blach S, Razavi-Shearer D
The case for simplifying and using absolute targets for viral hepatitis elimination goals.
J Viral Hepat. 2020 Sep 26. doi: 10.1111/jvh.13412.
PubMed Abstract available

MARTINEZ SANZ J, Vivancos MJ, Sanchez-Conde M, Gomez-Ayerbe C, et al
Hepatitis C and HIV combined screening in primary care: a cluster randomized trial.
J Viral Hepat. 2020 Sep 26. doi: 10.1111/jvh.13413.
PubMed Abstract available

JOHNSON PJ, Berhane S, Walker AJ, Gordon FH, et al
Impact Of Direct Acting Antiviral Agents On Liver Function In Patients With Chronic Hepatitis C Virus Infection.
J Viral Hepat. 2020 Sep 26. doi: 10.1111/jvh.13408.
PubMed Abstract available

RODRIGUEZ-TAJES S, Miralpeix A, Costa J, Lopez-Sune E, et al
Low risk of hepatitis b reactivation in patients with severe COVID-19 who receive immunosuppressive therapy.
J Viral Hepat. 2020 Sep 24. doi: 10.1111/jvh.13410.
PubMed Abstract available

ZHANG Y, Jiang X, Zhao Y, Xu Y, et al
Effect of baseline resistance-associated substitutions on the efficiency of glecaprevir/pibrentasvir in chronic hepatitis C subjects: A Meta-analysis.
J Viral Hepat. 2020 Sep 22. doi: 10.1111/jvh.13409.
PubMed Abstract available

THAUNG YM, Simion Chasela C C, Chew KW, Minior T, et al
Treatment outcomes and costs of a simplified antiviral treatment strategy for hepatitis C among monoinfected and HIV and/or hepatitis B virus co-infected patients in Myanmar.
J Viral Hepat. 2020 Sep 16. doi: 10.1111/jvh.13405.
PubMed Abstract available

WU J, Yu J, Shi X, Li W, et al
Epidemiological and Clinical Characteristics of 70 Cases of Coronavirus Disease and Concomitant Hepatitis B Virus Infection: A Multicenter Descriptive Study.
J Viral Hepat. 2020 Sep 14. doi: 10.1111/jvh.13404.
PubMed Abstract available

CHEN JY, Cheng PN, Chiu YC, Chiu HC, et al
Persistent Augmentation of Central Arterial Stiffness Following Viral Clearance by Direct Acting Antivirals in Chronic Hepatitis C.
J Viral Hepat. 2020 Sep 14. doi: 10.1111/jvh.13406.
PubMed Abstract available

BEEBEEJAUN K, Amin Z, Letley L, Kara E, et al
Impact of a nurse-led enhanced monitoring, management and contact tracing intervention for chronic hepatitis B in England, 2015-2017.
J Viral Hepat. 2020 Sep 14. doi: 10.1111/jvh.13403.
PubMed Abstract available

LIEM KS, Wong DK, Fung S, Zahirieh A, et al
Maintained virologic suppression and renal function with reduced dose tenofovir disoproxil fumarate in renally impaired chronic hepatitis B patients.
J Viral Hepat. 2020 Sep 8. doi: 10.1111/jvh.13401.
PubMed Abstract available

LINDGREN P, Lofvendahl S, Bradvik G, Weiland O, et al
Reduced work absenteeism in patients with hepatitis C treated with second-generation direct-acting antivirals.
J Viral Hepat. 2020 Sep 8. doi: 10.1111/jvh.13398.
PubMed Abstract available

VAN DIJK M, Drenth JPH
Loss to follow-up in the hepatitis C care cascade: A substantial problem but opportunity for micro-elimination.
J Viral Hepat. 2020 Sep 8. doi: 10.1111/jvh.13399.
PubMed Abstract available

WUNGU CDK, Ariyanto FC, Prabowo GI, Soetjipto, et al
Meta-analysis: Association between hepatitis B virus preS mutation and hepatocellular carcinoma risk.
J Viral Hepat. 2020 Sep 7. doi: 10.1111/jvh.13402.
PubMed Abstract available

LIU Y, Chang S, Martin R, Flaherty J, et al
Characterization of Hepatitis B virus polymerase mutations A194T and CYEI and tenofovir disoproxil fumarate or tenofovir alafenamide resistance.
J Viral Hepat. 2020 Sep 7. doi: 10.1111/jvh.13397.
PubMed Abstract available

CON D, Goodwin T, Majeed A, Roberts S, et al
Comparison of 48-week efficacy of tenofovir vs entecavir for patients with chronic hepatitis B: A network meta-analysis.
J Viral Hepat. 2020 Sep 7. doi: 10.1111/jvh.13400.
PubMed Abstract available

MIZOKAMI M, Liu LJ, Fujiyama N, Littman M, et al
Real-world safety and effectiveness of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C virus genotype 1 in Japan.
J Viral Hepat. 2020 Sep 1. doi: 10.1111/jvh.13395.
PubMed Abstract available

BEUDEKER BJB, Groothuismink ZMA, de Man RA, Witjes CDM, et al
Hepatitis B core-related antigen levels predict recurrence-free survival in patients with HBV associated early stage hepatocellular carcinoma: results from a Dutch long-term follow-up study.
J Viral Hepat. 2020 Sep 1. doi: 10.1111/jvh.13394.
PubMed Abstract available

PRINCE DS, Pipicella JL, Fraser M, Alvaro F, et al
Screening Emergency Admissions at Risk of Chronic Hepatitis C (SEARCH) to diagnose or "re-diagnose" infections is effective in Australia.
J Viral Hepat. 2020 Sep 1. doi: 10.1111/jvh.13393.
PubMed Abstract available

PALLERLA SR, Schembecker S, Meyer CG, Linh LTK, et al
Hepatitis E virus genome detection in commercial pork livers and pork meat products in Germany.
J Viral Hepat. 2020 Sep 1. doi: 10.1111/jvh.13396.
PubMed Abstract available

August 2020

WADE AJ, Doyle JS, Draper B, Howell J, et al
In support of community-based hepatitis C treatment with triage of people at risk of cirrhosis to specialist care.
J Viral Hepat. 2020 Aug 29. doi: 10.1111/jvh.13391.
PubMed Abstract available

VAN NUIL JI, Umutesi G, Shumbusho F, Kateera F, et al
Improved quality of life following direct-acting antiviral treatment for chronic hepatitis C infection in Rwanda: Results from a clinical trial in sub-Saharan Africa (the SHARED study).
J Viral Hepat. 2020 Aug 28. doi: 10.1111/jvh.13386.
PubMed Abstract available

SYED TA, Cherian R, Lewis S, Sterling RK, et al
Telemedicine HCV Treatment in Department of Corrections Results in High SVR In Era of Direct-Acting Antivirals.
J Viral Hepat. 2020 Aug 27. doi: 10.1111/jvh.13392.
PubMed Abstract available

ARNONE OC, Serranti D, Bartolini E, Mastrangelo G, et al
Chronic Hepatitis B in Children, Report of a Single-Centre Longitudinal Study on 152 Children.
J Viral Hepat. 2020 Aug 27. doi: 10.1111/jvh.13382.
PubMed Abstract available

LI S, Li M, He Q, Liang Z, et al
Characterization of hepatitis E virus natural infection in farmed rabbits.
J Viral Hepat. 2020 Aug 27. doi: 10.1111/jvh.13387.
PubMed Abstract available

TAO YC, Chen EQ
Rely to: "Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment: Methodological issues".
J Viral Hepat. 2020 Aug 27. doi: 10.1111/jvh.13390.
PubMed Abstract available

KIM SU, Chon YE, Seo YS, Lee HW, et al
A multi-center study of trends in hepatitis B virus-related hepatocellular carcinoma risk over time during long-term entecavir therapy.
J Viral Hepat. 2020 Aug 27. doi: 10.1111/jvh.13384.
PubMed Abstract available

PFLUGER LS, Schulze Zur Wiesch J, Polywka S, Lutgehetmann M, et al
Hepatitis delta virus propagation enabled by hepatitis C virus - scientifically intriguing; but is it relevant to clinical practice?
J Viral Hepat. 2020 Aug 27. doi: 10.1111/jvh.13385.
PubMed Abstract available

CHEN J, Wang Y, Wu J
Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment: Methodological issues.
J Viral Hepat. 2020 Aug 27. doi: 10.1111/jvh.13383.
PubMed Abstract available

PHILLIPS C, O'Sullivan, Schulkind J, Jones CJ, et al
Authors' reply to letter: In support of community-based hepatitis C treatment with triage of people at risk of cirrhosis to specialist care'.
J Viral Hepat. 2020 Aug 27. doi: 10.1111/jvh.13389.
PubMed Abstract available

SUNG JC, Wyatt B, Perumalswami PV, Branch A, et al
Response to "Hepatitis C Cure Improved Patient-reported Outcomes in Patients with and without Liver Fibrosis in a Prospective Study at a Large Urban Medical Center".
J Viral Hepat. 2020 Aug 25. doi: 10.1111/jvh.13381.
PubMed Abstract available

GIULIANI R, Casigliani V, Fornili M, Sebastiani T, et al
HCV micro-elimination in two prisons in Milan, Italy: a model of care.
J Viral Hepat. 2020 Aug 20. doi: 10.1111/jvh.13376.
PubMed Abstract available

MENDIZABAL M, Testa P, Rojas M, Colaci CS, et al
Pilot study using the ECHO model to enhance linkage to care for patients with hepatitis C in the custodial setting.
J Viral Hepat. 2020 Aug 19. doi: 10.1111/jvh.13374.
PubMed Abstract available

MORA M, Goodyear T, Marcellin F, Shoveller J, et al
Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH).
J Viral Hepat. 2020 Aug 18. doi: 10.1111/jvh.13378.
PubMed Abstract available

DONG Y, Li M, Zhu S, Gao X, et al
De novo combination antiviral therapy in e antigen-negative chronic hepatitis B virus-infected pediatric patients with advanced fibrosis.
J Viral Hepat. 2020 Aug 18. doi: 10.1111/jvh.13372.
PubMed Abstract available

HAMADEH A, Haines A, Feng Z, Thein HH, et al
Estimating chronic hepatitis C prevalence in British Columbia and Ontario, Canada using population-based cohort studies.
J Viral Hepat. 2020 Aug 18. doi: 10.1111/jvh.13373.
PubMed Abstract available

RAHAL H, Boutros S, Farhat M, Kullar R, et al
Estimating Pediatric Hepatitis C Prevalence in the United States.
J Viral Hepat. 2020 Aug 18. doi: 10.1111/jvh.13377.
PubMed Abstract available

MEDRZYCKI M, Kamili S, Purdy MA
Hepatitis A Virus Survival on Drug Paraphernalia.
J Viral Hepat. 2020 Aug 18. doi: 10.1111/jvh.13379.
PubMed Abstract available

BARRE T, Nishimwe ML, Protopopescu C, Marcellin F, et al
Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C-infected patients (ANRS CO22 Hepather cohort).
J Viral Hepat. 2020 Aug 18. doi: 10.1111/jvh.13380.
PubMed Abstract available

MESSINA V, Russo A, Parente E, Russo G, et al
Innovative procedures for micro-elimination of hcv infection in persons who use drugs.
J Viral Hepat. 2020 Aug 18. doi: 10.1111/jvh.13375.
PubMed Abstract available

ZENG W, Liu M, Peng S, Yu G, et al
Is the life-long entecavir treatment really inevitable in chronic hepatitis B patients?
J Viral Hepat. 2020 Aug 2. doi: 10.1111/jvh.13369.
PubMed Abstract available

HUANG Y, Li X, Zheng X, Tian X, et al
Bayesian Network to Predict Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients.
J Viral Hepat. 2020 Aug 2. doi: 10.1111/jvh.13368.
PubMed Abstract available

LIU Z, Shi O, Zhang T, Jin L, et al
Disease burden of viral hepatitis A, B, C, and E: a systematic analysis.
J Viral Hepat. 2020 Aug 2. doi: 10.1111/jvh.13371.
PubMed Abstract available

PERPINAN E, Perez-Del-Pulgar S, Londono MC, Marino Z, et al
Chronic genotype 1 hepatitis C along with cirrhosis drives a persistent imprint in virus-specific CD8(+) T cells after direct-acting antiviral therapies.
J Viral Hepat. 2020 Aug 2. doi: 10.1111/jvh.13370.
PubMed Abstract available

July 2020

WRANKE A, Hardtke S, Heidrich B, Dalekos G, et al
Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta.
J Viral Hepat. 2020 Jul 24. doi: 10.1111/jvh.13366.
PubMed Abstract available

CASTRO FILHO E, Piedade J, Castro R, Luz PM, et al
Effectiveness of direct-acting agents for chronic hepatitis C treatment in South America: a systematic review and meta-analysis.
J Viral Hepat. 2020 Jul 24. doi: 10.1111/jvh.13364.
PubMed Abstract available

YIM HJ, Suh SJ, Jung YK, Hwang SG, et al
Tenofovir-based combination therapy or monotherapy for multi-drug resistant chronic hepatitis B: Long-term data from a multicenter cohort study.
J Viral Hepat. 2020 Jul 24. doi: 10.1111/jvh.13363.
PubMed Abstract available

FREELAND C, Vader D, Cohen C, George B, et al
A Predictive Model for Hepatitis B Infection Among High-Risk Adults Using a Community-Based Sample in Greater Philadelphia.
J Viral Hepat. 2020 Jul 23. doi: 10.1111/jvh.13365.
PubMed Abstract available

IRVIN R, Ntiri-Reid B, Kleinman M, Agee T, et al
Sharing the Cure: Building Primary Care and Public Health Infrastructure to Improve the Hepatitis C Care Continuum in Maryland.
J Viral Hepat. 2020 Jul 15. doi: 10.1111/jvh.13360.
PubMed Abstract available

WONG SW, Chan WK, Mohamed R
Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B.
J Viral Hepat. 2020 Jul 15. doi: 10.1111/jvh.13361.
PubMed Abstract available

DAI CY, Huang JF, Chuang WL, Yu ML, et al
Severe acute exacerbation of HCV infection in cancer patients who undergo chemotherapy: some issues.
J Viral Hepat. 2020 Jul 5. doi: 10.1111/jvh.13358.
PubMed Abstract available

DIMOVA RB, Rude E, Talal AH
Age and Risk-Factor Based Serologic Screening for Hepatitis C Virus among an Urban, High-Risk Population.
J Viral Hepat. 2020 Jul 2. doi: 10.1111/jvh.13359.
PubMed Abstract available

June 2020

NANGIA G, Vierling JM, Kwo P, Brown DD, et al
Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: integrated analysis from clinical trials.
J Viral Hepat. 2020 Jun 28. doi: 10.1111/jvh.13357.
PubMed Abstract available

DALBENI A, Romano S, Bevilacqua M, Piccoli A, et al
Beneficial effects of DAAs on cardiac function and structure in hepatitis C patients with low-moderate liver fibrosis.
J Viral Hepat. 2020 Jun 27. doi: 10.1111/jvh.13355.
PubMed Abstract available

RINGLANDER J, Skoglund C, Prakash K, Andersson ME, et al
Deep sequencing of liver explant transcriptomes reveals extensive expression from integrated hepatitis B virus DNA.
J Viral Hepat. 2020 Jun 27. doi: 10.1111/jvh.13356.
PubMed Abstract available

CHEN YC, Thio CL, Kamangar F, Cox AL, et al
Evolving trends in the prevalence of hepatitis C virus antibody positivity among HIV-infected men in a community-based primary care setting.
J Viral Hepat. 2020 Jun 24. doi: 10.1111/jvh.13354.
PubMed Abstract available

VERBINNEN T, Hodari M, Talloen W, Berke JM, et al
Virology analysis of chronic hepatitis B infected patients treated for 28 days with JNJ-56136379 monotherapy.
J Viral Hepat. 2020 Jun 24. doi: 10.1111/jvh.13351.
PubMed Abstract available

ABE H, Ushijima Y, Bikangui R, Ondo GN, et al
First evidence for continuous circulation of hepatitis A virus subgenotype IIA in Central Africa.
J Viral Hepat. 2020 Jun 21. doi: 10.1111/jvh.13348.
PubMed Abstract available

YOUSIF MM, Ahmed H, Elsadek HM, Shendi AM, et al
Real-World Safety and Effectiveness Of Retreatment Of Egyptian Chronic Hepatitis C Patients Not Responding to NS5A Inhibitor-Based Therapies.
J Viral Hepat. 2020 Jun 21. doi: 10.1111/jvh.13349.
PubMed Abstract available

ZHANG H, Yan X, Yang C, Zhan Q, et al
Intrahepatic T helper 17 cells recruited by hepatitis B virus X antigen-activated hepatic stellate cells exacerbate the progression of chronic hepatitis B virus infection.
J Viral Hepat. 2020 Jun 19. doi: 10.1111/jvh.13352.
PubMed Abstract available

CUADRADO A, Perello C, Cabezas J, Llerena S, et al
Update on epidemiology of hepatitis B in a low-endemic European country: there is still much to do.
J Viral Hepat. 2020 Jun 19. doi: 10.1111/jvh.13350.
PubMed Abstract available

HWA YOUNG C, Mai Thi H, Kim KA, Cho H, et al
Association between viral hepatitis infection and Parkinson's disease: A population-based prospective study.
J Viral Hepat. 2020 Jun 17. doi: 10.1111/jvh.13346.
PubMed Abstract available

OTHMAN B, Al-Najjar MAA, Othman D, Al-Qudah R, et al
Prevalence, knowledge of and attitude towards Hepatitis B virus among pregnant females in Jordan.
J Viral Hepat. 2020 Jun 7. doi: 10.1111/jvh.13342.
PubMed Abstract available

WU J, Huang F, Ling Z, Liu S, et al
Altered fecal microbiota on the expression of Th Cells responses in the exacerbation of patients with hepatitis E infection.
J Viral Hepat. 2020 Jun 5. doi: 10.1111/jvh.13344.
PubMed Abstract available

SAINE ME, Szymczak JE, Moore TM, Bamford LP, et al
Determinants of Stigma among Patients with Hepatitis C Virus (HCV) Infection.
J Viral Hepat. 2020 Jun 5. doi: 10.1111/jvh.13343.
PubMed Abstract available

CHON YE, Jung KS, Ha Y, Kim MN, et al
High body mass index hinders fibrosis improvement in patients receiving long-term tenofovir therapy in hepatitis B virus-related cirrhosis.
J Viral Hepat. 2020 Jun 5. doi: 10.1111/jvh.13345.
PubMed Abstract available

MINA M, Underwood A, Eltahla A, Wu BR, et al
Anti-Envelope antibody responses in highly-exposed seronegative individuals may be associated with protection from HCV infection.
J Viral Hepat. 2020 Jun 4. doi: 10.1111/jvh.13339.
PubMed Abstract available

JACK K, Linsley P, JamesThomson B, Irving WL, et al
How do people in prison feel about opt-out hepatitis C virus testing?
J Viral Hepat. 2020 Jun 2. doi: 10.1111/jvh.13338.
PubMed Abstract available

KAPLAN DE, Medvedeva E, Serper M
Care Quality and Outcomes among U.S. Veterans with Chronic Hepatitis B in the Hepatitis C Direct Acting Antiviral Era.
J Viral Hepat. 2020 Jun 2. doi: 10.1111/jvh.13340.
PubMed Abstract available

POLLOCK KG, McDonald SA, Gunson R, McLeod A, et al
Real-world utility of HCV core antigen as an alternative to HCV RNA testing: Implications for viral load and genotype.
J Viral Hepat. 2020 Jun 1. doi: 10.1111/jvh.13337.
PubMed Abstract available

May 2020

CONNOLEY D, Francis-Graham S, Storer M, Ekeke N, et al
Detection, stratification, and treatment of hepatitis C positive prisoners in the United Kingdom prison estate: Development of a pathway of care to facilitate the elimination of hepatitis C in a London prison.
J Viral Hepat. 2020 May 25. doi: 10.1111/jvh.13336.
PubMed Abstract available

DE LEDINGHEN V, Lusivika-Nzinga C, Bronowicki JP, Zoulim F, et al
Sofosbuvir-based regimens are suboptimal in patients with genotype 2 chronic hepatitis C infection: Real-life experience from the HEPATHER ANRS CO22 cohort.
J Viral Hepat. 2020 May 21. doi: 10.1111/jvh.13321.
PubMed Abstract available

DIETZ J, Kalinina OV, Vermehren J, Peiffer KH, et al
Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection.
J Viral Hepat. 2020 May 12. doi: 10.1111/jvh.13322.
PubMed Abstract available

YE W, Li X
Hepatitis C cure improved patient-reported outcomes in patients with and without liver fibrosis.
J Viral Hepat. 2020 May 12. doi: 10.1111/jvh.13323.
PubMed Abstract available

KIM NG, Kullar R, Khalil H, Saab S, et al
Meeting the WHO Hepatitis C Virus Elimination Goal: Review of Treatment in Pediatrics.
J Viral Hepat. 2020 May 9. doi: 10.1111/jvh.13317.
PubMed Abstract available

LI MR, Xu ZG, Lu JH, Zheng HW, et al
Clinical Features of Hepatitis B Patients at Immune-tolerance Phase with Basal Core Promoter and/or Precore Mutations.
J Viral Hepat. 2020 May 8. doi: 10.1111/jvh.13315.
PubMed Abstract available

NING G, Zhen LM, Xu WX, Li XJ, et al
Suppression of complement component2 expression by hepatitis B virus contributes to the viral persistence in chronic hepatitis B patients.
J Viral Hepat. 2020 May 8. doi: 10.1111/jvh.13319.
PubMed Abstract available

YUEN L, Revill PA, Rosenberg G, Wagner J, et al
HBV variants are common in the "immune-tolerant"phase of chronic hepatitis B.
J Viral Hepat. 2020 May 8. doi: 10.1111/jvh.13318.
PubMed Abstract available

LIM TS, Lee HW, Lee JI, Kim IH, et al
Predictive score for hepatocellular carcinoma after hepatitis B eantigen loss in patients treated with entecavir or tenofovir.
J Viral Hepat. 2020 May 7. doi: 10.1111/jvh.13316.
PubMed Abstract available

JEON MY, Lee JS, Lee HW, Kim BK, et al
Entecavirandtenofoviron renal function in patients with hepatitis B virus related hepatocellular carcinoma.
J Viral Hepat. 2020 May 4. doi: 10.1111/jvh.13313.
PubMed Abstract available

LEE WM, King WC, Schwarz KB, Rule J, et al
Prevalence and Clinical Features of Patients with Concurrent HBsAg and Anti-HBs: Evaluation of the Hepatitis B Research Network Cohort.
J Viral Hepat. 2020 May 4. doi: 10.1111/jvh.13312.
PubMed Abstract available

PAN YC, Jia ZF, Wang YQ, Yang N, et al
The role of cesarean section and non-breastfeeding in preventing mother-to-child transmission of hepatitis B virus in HBsAg and HBeAg positive mothers: results from a prospective cohort study and a meta-analysis.
J Viral Hepat. 2020 May 3. doi: 10.1111/jvh.13314.
PubMed Abstract available

ZHANG M, O'Keefe D, Iwamoto M, Sann K, et al
High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia.
J Viral Hepat. 2020 May 2. doi: 10.1111/jvh.13311.
PubMed Abstract available

April 2020

CARRASCO I, Sainz T, Antoinette Frick M, de Ory SJ, et al
Response to Direct Acting Antivirals for hepatitis C treatment in vertically HIV/HCV co-infected patients.
J Viral Hepat. 2020 Apr 29. doi: 10.1111/jvh.13308.
PubMed Abstract available

CHIU WN, Hung CH, Lu SN, Chen MY, et al
Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection:a multicenter pooled analysis in Taiwan.
J Viral Hepat. 2020 Apr 28. doi: 10.1111/jvh.13305.
PubMed Abstract available

HONG CY, Sinn DH, Kang D, Paik SW, et al
Incidence of extrahepatic cancers among individuals with chronic hepatitis B or C virus infection: Anationwide cohort study.
J Viral Hepat. 2020 Apr 27. doi: 10.1111/jvh.13304.
PubMed Abstract available

YIP TC, Wong VW, Chan HL, Tse YK, et al
Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B.
J Viral Hepat. 2020 Apr 27. doi: 10.1111/jvh.13307.
PubMed Abstract available

STROFFOLINI T, Ciancio A, Furlan C, Vinci M, et al
Migratory flow and hepatitis Delta infection in Italy: a new challenge at the beginning of the third millennium.
J Viral Hepat. 2020 Apr 27. doi: 10.1111/jvh.13310.
PubMed Abstract available

CHO JY, Sohn W, Paik YH, Gwak GY, et al
Long-term hepatitis B surface antigen (HBsAg) kinetics during entecavir treatment in Korean patients - functional cure unlikely.
J Viral Hepat. 2020 Apr 27. doi: 10.1111/jvh.13306.
PubMed Abstract available

WANG H, Wang M, Huang J, Xu R, et al
Novel hepatitis B virus surface antigen mutations associated with occult genotype Bhepatitis B virus infection affect HBsAgdetection.
J Viral Hepat. 2020 Apr 26. doi: 10.1111/jvh.13309.
PubMed Abstract available

LEE J, Park JY, Yang SJ, Lee JY, et al
Renal safety of tenofovir disoproxil fumarate and entecavir with hepatitis B immunoglobulin in liver transplant patients.
J Viral Hepat. 2020 Apr 17. doi: 10.1111/jvh.13291.
PubMed Abstract available

LI YR, Chen WC, Tsai WL, Cheng JS, et al
Severe acute exacerbation of HCV infection in cancer patients who undergo chemotherapy without anti-viral prophylaxis.
J Viral Hepat. 2020 Apr 16. doi: 10.1111/jvh.13302.
PubMed Abstract available

AMOUGOU-ATSAMA M, Atangana PJA, Noah Noah D, Fewou Moundipa P, et al
The role of hepatitis C virus genotypes and core mutations inhepatocellular carcinomain Cameroon.
J Viral Hepat. 2020 Apr 16. doi: 10.1111/jvh.13303.
PubMed Abstract available

HUANG X, Young KH, Guo W, Wang Y, et al
Identification of Hepatitis B virus etiologic antigens, HBx and Pre-S2, in Diffuse Large B-cell Lymphoma.
J Viral Hepat. 2020 Apr 13. doi: 10.1111/jvh.13301.
PubMed Abstract available

ABU FREHA N, Wainstock T, Poupko L, Shemer Avni Y, et al
Maternal hepatitis B or hepatitis C virus carrier s tatus and long-term infectious morbidity of the offspring: A population-based cohort study.
J Viral Hepat. 2020 Apr 9. doi: 10.1111/jvh.13300.
PubMed Abstract available

DESAI M, White E, Vora N, Gilson R, et al
High incidence of Hepatitis C virus infection observed in the PROUD study of HIV pre-exposure prophylaxis.
J Viral Hepat. 2020 Apr 3. doi: 10.1111/jvh.13297.
PubMed Abstract available

TSENG CW, Wu SF, Chen CY, Ho YC, et al
Characteristics of Regulatory T Cell Function in Patients with Chronic Hepatitis B and C Coinfection.
J Viral Hepat. 2020 Apr 3. doi: 10.1111/jvh.13298.
PubMed Abstract available

PAN XB
Reply to the letter by Peng. HBV transmission route among children in China.
J Viral Hepat. 2020;27:462.
PubMed

PENG S
HBV transmission route among children in China. A letter in response to Young Chinese children without seroprotective hepatitis B surface antibody could be at risk of hepatitis B virus infection through horizontal transmission.
J Viral Hepat. 2020;27:461.
PubMed

March 2020

BEYAN C, Beyan E
Plateletcrit may not be an index for predicting liver fibrosis in patients with chronic hepatitis B.
J Viral Hepat. 2020 Mar 20. doi: 10.1111/jvh.13289.
PubMed Abstract available

HUANG R, Wang J, Xia J, Wu C, et al
Reply to the letter by Beyan et al "Plateletcrit may not be an index for predicting of liver fibrosis in patients with chronic hepatitis B".
J Viral Hepat. 2020 Mar 20. doi: 10.1111/jvh.13288.
PubMed Abstract available

SPREAFICO M, Raffaele L, Guarnori I, Foglieni B, et al
Prevalence and 9-year incidence of hepatitis E virus infection among north italian blood donors: Estimated transfusion risk.
J Viral Hepat. 2020 Mar 20. doi: 10.1111/jvh.13296.
PubMed Abstract available

CHEN YP, Huang LW, Lin XY, Hu XM, et al
Alanine Aminotransferase Influencing Performances of Routine Available Tests Detecting Hepatitis B Related Cirrhosis.
J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13293.
PubMed Abstract available

VAN SANTEN DK, Sacks-Davis R, Doyle JS, Scott N, et al
Measuring hepatitis C virus elimination as a public health threat:beyond global targets.
J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13294.
PubMed Abstract available

JANJUA NZ, Wong S, Darvishian M, Butt ZA, et al
The impact of SVR from direct acting antiviral and interferon- based treatments for HCV on hepatocellular carcinoma risk.
J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13295.
PubMed Abstract available

MEYER M, Bondy L, Koivu S, Koval J, et al
New Hepatitis C Diagnoses in Ontario, Canada are associated with the Local Prescription Patterns of a Controlled Release Opioid.
J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13292.
PubMed Abstract available

FONSECA MA, Ling Zhi Jie J, Al-Siyabi O, Co-Tanko V, et al
The efficacy of hepatitis B treatments in achieving HBsAgseroclearance: a systematic review and meta-analysis.
J Viral Hepat. 2020 Mar 14. doi: 10.1111/jvh.13283.
PubMed Abstract available

BRADSHAW D, Vasylyeva TI, Davis C, Pybus OG, et al
Transmission of hepatitis C virus in HIV-positive and PrEP-using MSM in England.
J Viral Hepat. 2020 Mar 1. doi: 10.1111/jvh.13286.
PubMed Abstract available

DARVISHIAN M, Wong S, Binka M, Yu A, et al
Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies.
J Viral Hepat. 2020;27:243-260.
PubMed Abstract available

PLATT L, French CE, McGowan CR, Sabin K, et al
Prevalence and burden of HBV co-infection among people living with HIV: A global systematic review and meta-analysis.
J Viral Hepat. 2020;27:294-315.
PubMed Abstract available

February 2020

RIVEIRO-BARCIELA M, Rando-Segura A, Barreira-Diaz A, Bes M, et al
Unexpected long-lasting anti-HEV IgM positivity: Is HEV antigen a better serological marker for hepatitis E infection diagnosis?
J Viral Hepat. 2020 Feb 27. doi: 10.1111/jvh.13285.
PubMed Abstract available

BIELEN R, Koc OM, Busschots D, Verrando R, et al
Validation of hepatitis C virus RNA detection using capillary blood by fingerprick (GenXpert system)- Hepatitis C fingerprick study.
J Viral Hepat. 2020 Feb 27. doi: 10.1111/jvh.13284.
PubMed Abstract available

DENG Y, Campbell F, Han K, Theodore D, et al
Randomized Clinical Trials Towards a Single-Visit Cure for Chronic Hepatitis C: Oral GSK2878175 and Injectable RG-101 in Chronic Hepatitis C Patients and Long-Acting Injectable GSK2878175 in Healthy Participants.
J Viral Hepat. 2020 Feb 24. doi: 10.1111/jvh.13282.
PubMed Abstract available

KNOP V, Mauss S, Goeser T, Geier A, et al
Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C (HCV) infection receiving direct acting antiviral therapy- results from the German Hepatitis C-Registry (DHC-R).
J Viral Hepat. 2020 Feb 24. doi: 10.1111/jvh.13280.
PubMed Abstract available

MIRANDA AC, Mendez J, Serrao R, Vale F, et al
Chronic hepatitis C treatment in HIV Co-infection in Portugal: Results from a cohort of 2133 patients presented by GEPCOI (Portuguese Coinfection Study Group).
J Viral Hepat. 2020 Feb 24. doi: 10.1111/jvh.13281.
PubMed Abstract available

KIM J, Chung SJ, Sinn DH, Lee KW, et al
Hepatitis B reactivation after kidney transplantation in hepatitis B surface antigen-negative, core antibody-positive recipients.
J Viral Hepat. 2020 Feb 14. doi: 10.1111/jvh.13279.
PubMed Abstract available

MOJSIEJCZUK L, Torres C, Flichman D, Campos RH, et al
Long-term evolution of hepatitis B virus genotype F: strong association between viral diversification and the prehistoric settlement of Central and South America.
J Viral Hepat. 2020 Feb 12. doi: 10.1111/jvh.13273.
PubMed Abstract available

VAN CAMPENHOUT MJH, van Bommel F, Pfefferkorn M, Fischer J, et al
Serum hepatitis B virus rna predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B.
J Viral Hepat. 2020 Feb 12. doi: 10.1111/jvh.13272.
PubMed Abstract available

SHIHA G, Mousa N, Soliman R, Mikhail NN, et al
Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study.
J Viral Hepat. 2020 Feb 12. doi: 10.1111/jvh.13276.
PubMed Abstract available

LIU Z, Mao X, Yu K, Suo C, et al
Prevalence of HCV Resistance-Associated Substitutions amongTreatment FailurePatients receiving Direct-Acting Antiviral Agents.
J Viral Hepat. 2020 Feb 12. doi: 10.1111/jvh.13270.
PubMed Abstract available

CIMINI E, Sacchi A, Grassi G, Casetti R, et al
Persistent gamma delta T-cell dysfunction in HCV/HIV co-infection despite direct-acting antiviral therapy induced cure.
J Viral Hepat. 2020 Feb 12. doi: 10.1111/jvh.13277.
PubMed Abstract available

HIGASHI RT, Jain MK, Quirk L, Rich NE, et al
Patient and Provider-Level Barriers to Hepatitis C Screening and Linkage to Care: A Mixed-Methods Evaluation.
J Viral Hepat. 2020 Feb 11. doi: 10.1111/jvh.13278.
PubMed Abstract available

TAO YC, Wang ML, Zhang DM, Wu DB, et al
Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment.
J Viral Hepat. 2020 Feb 11. doi: 10.1111/jvh.13275.
PubMed Abstract available

FALADE-NWULIA O, Ward KM, McCormick S, Mehta SH, et al
Network-based recruitment of people who inject drugs for hepatitis C testing and linkage to care.
J Viral Hepat. 2020 Feb 11. doi: 10.1111/jvh.13274.
PubMed Abstract available

January 2020

SHIHA G, Soliman R, Serwah A, Mikhail NN, et al
A same day "test and treat" model for chronic HCV and HBV infection: Results from two community-based pilot studies in Egypt.
J Viral Hepat. 2020 Jan 30. doi: 10.1111/jvh.13268.
PubMed Abstract available

MD SAID R, Mohd Zain R, Chan HK, Soelar SA, et al
Find the Missing Millions: Malaysia's Experience with Nationwide Hepatitis C Screening Campaign in the General Population.
J Viral Hepat. 2020 Jan 29. doi: 10.1111/jvh.13267.
PubMed Abstract available

CAVEN M, Robinson EM, Eriksen AJ, Fletcher EH, et al
Hepatitis C Diagnosis and Treatment, Impact on Engagement and Behaviour of People Who Inject Drugs, a service evaluation, the Hooked C project.
J Viral Hepat. 2020 Jan 29. doi: 10.1111/jvh.13269.
PubMed Abstract available

GOEL A, Padmaprakash KV, Benjamin M, Katiyar H, et al
Temporal profile of HEV RNA concentration in blood and stool from patients with acute uncomplicated hepatitis E in a region with genotype 1 predominance.
J Viral Hepat. 2020 Jan 29. doi: 10.1111/jvh.13266.
PubMed Abstract available

WANG J, Xia J, Yan X, Yang Y, et al
Plateletcrit as a potential index for predicting liver fibrosis in chronic hepatitis B.
J Viral Hepat. 2020 Jan 25. doi: 10.1111/jvh.13264.
PubMed Abstract available

LIU CH, Yang SS, Peng CY, Lin WT, et al
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment.
J Viral Hepat. 2020 Jan 25. doi: 10.1111/jvh.13265.
PubMed Abstract available

TRAN TH, Nguyen BT, Nguyen TA, Pham TTP, et al
Dried blood spots perform well to identify patients with active HCV infection in Vietnam.
J Viral Hepat. 2020 Jan 24. doi: 10.1111/jvh.13263.
PubMed Abstract available

POURMARZI D, Smirnov A, Hall L, Thompson H, et al
Enablers and barriers for the provision of community-based HCV treatment: a case study of a real-world practice.
J Viral Hepat. 2020 Jan 20. doi: 10.1111/jvh.13259.
PubMed Abstract available

OU Q, Guo J, Zeng Y, Chen H, et al
Insights for clinical diagnostic indicators of virus and host in chronic hepatitis B infection.
J Viral Hepat. 2020 Jan 18. doi: 10.1111/jvh.13260.
PubMed Abstract available

POORDAD F, Castro RE, Asatryan A, Aguilar H, et al
Long-Term Safety and Efficacy Results in Hepatitis C Virus Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir +/- Ribavirin in the TOPAZ-I and TOPAZ-II Trials.
J Viral Hepat. 2020 Jan 18. doi: 10.1111/jvh.13261.
PubMed Abstract available

TRAM J, Le Baccon-Sollier P, Bollore K, Ducos J, et al
RNA testing for the diagnosis of acute hepatitis A during the 2017 outbreak in France.
J Viral Hepat. 2020 Jan 2. doi: 10.1111/jvh.13255.
PubMed Abstract available

YAMAMICHI S, Miuma S, Wada T, Masumoto H, et al
Deep sequence analysis of NS5A resistance-associated substitution changes in patients reinfected with the hepatitis C virus after liver transplantation.
J Viral Hepat. 2020 Jan 2. doi: 10.1111/jvh.13256.
PubMed Abstract available

FEDORCHENKO SV, Martynovych T, Klimenko Z, Yanchenko V, et al
Retreatment of patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous direct acting antiviral therapy including first- and second-generation NS5A inhibitors with ombitasvir/ paritaprevir/ ritonavir, dasabuvir + sofosbuvir + r
J Viral Hepat. 2020 Jan 2. doi: 10.1111/jvh.13254.
PubMed Abstract available

December 2019

CHIEN RN, Liaw YF
Re-treatment for severe hepatitis flare in HBeAg-negative chronic hepatitis B: An appraisal with combined HBsAg/ALT kinetics.
J Viral Hepat. 2019 Dec 23. doi: 10.1111/jvh.13253.
PubMed Abstract available

XIAO Y, Howell J, van Gemert C, Thompson AJ, et al
Enhancing the hepatitis B care cascade in Australia: a cost-effectiveness model.
J Viral Hepat. 2019 Dec 19. doi: 10.1111/jvh.13252.
PubMed Abstract available

IRVIN R, Chander G, Ward KM, Manogue S, et al
Unreported Alcohol Use Was Common But Did Not Impact Hepatitis C Cure in HIV-Infected Persons Who Use Drugs.
J Viral Hepat. 2019 Dec 18. doi: 10.1111/jvh.13251.
PubMed Abstract available

WONG L, Cheung TH, Yim SF, Lao TT, et al
Prevalence and Impact of Hepatitis B Virus Infection in Ovarian Cancer Patients in an Endemic Area - a Retrospective Cohort Study.
J Viral Hepat. 2019 Dec 18. doi: 10.1111/jvh.13250.
PubMed Abstract available

IM JH, Woo HT, Ha B, Jung J, et al
Effectiveness of Single-Dose Administration of Inactivated Hepatitis A Virus Vaccination in the Republic of Korea Armed Forces, 2013-2016.
J Viral Hepat. 2019 Dec 18. doi: 10.1111/jvh.13249.
PubMed Abstract available

FONTANA RJ, Avigan MI, Janssen HLA, Regev A, et al
Liver safety assessment in clinical trials of new agents for chronic hepatitis B.
J Viral Hepat. 2019 Dec 11. doi: 10.1111/jvh.13223.
PubMed Abstract available

SONDERUP M, Dusheiko G, Desalegn H, Lemoine M, et al
Hepatitis B in sub-Saharan Africa - how many patients need therapy?
J Viral Hepat. 2019 Dec 4. doi: 10.1111/jvh.13247.
PubMed Abstract available

UDOMPAP P, Sukonrut K, Suvannarerg V, Pongpaibul A, et al
Prospective Comparison of Transient Elastography, Point Shear Wave Elastography, APRI, and FIB-4 for Staging Liver Fibrosis in Chronic Viral Hepatitis.
J Viral Hepat. 2019 Dec 4. doi: 10.1111/jvh.13246.
PubMed Abstract available

November 2019

GANE EJ, Charlton MR, Mohamed R, Sollano JD, et al
Asian Consensus Recommendations on Optimizing the Diagnosis and Initiation of Treatment of Hepatitis B Virus Infection in Resource-Limited Settings.
J Viral Hepat. 2019 Nov 30. doi: 10.1111/jvh.13244.
PubMed Abstract available

SULLIVAN RP, Davies J, Binks P, Dhurrkay RG, et al
Point of care and oral fluid Hepatitis B testing in remote Indigenous communities of northern Australia.
J Viral Hepat. 2019 Nov 29. doi: 10.1111/jvh.13243.
PubMed Abstract available

PAN XB, Yu J, Li HJ, Wu N, et al
Young Chinese children without seroprotective hepatitis B surface antibody could be at risk of hepatitis B virus infection through horizontal transmission.
J Viral Hepat. 2019 Nov 29. doi: 10.1111/jvh.13242.
PubMed Abstract available

BOYLE A, Marra F, Peters E, Datta S, et al
Eight weeks of Sofosbuvir/Velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis.
J Viral Hepat. 2019 Nov 22. doi: 10.1111/jvh.13239.
PubMed Abstract available

CRESPO J, Cuadrado A, Perello C, Cabezas J, et al
Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: data for designing a cost-effective elimination policy in Spain.
J Viral Hepat. 2019 Nov 22. doi: 10.1111/jvh.13238.
PubMed Abstract available

STARBIRD LE, Budhathoki C, Han HR, Sulkowski MS, et al
Nurse case management to improve the hepatitis C care continuum in HIV co-infection: Results of a randomized controlled trial.
J Viral Hepat. 2019 Nov 21. doi: 10.1111/jvh.13241.
PubMed Abstract available

BHANDARI R, Morey S, Hamoodi A, Thompson C, et al
High rate of hepatitis C re-infection following antiviral treatment in the North East England Prisons.
J Viral Hepat. 2019 Nov 21. doi: 10.1111/jvh.13240.
PubMed Abstract available

DA BL, Surana P, Takyar V, Kleiner DE, et al
Vibration-Controlled Transient Elastography for the Detection of Cirrhosis in Chronic Hepatitis D Infection.
J Viral Hepat. 2019 Nov 19. doi: 10.1111/jvh.13235.
PubMed Abstract available

SUNG JC, Bosh C, Wyatt B, Miller M, et al
Hepatitis C Cure Improved Patient-reported Outcomes in Patients with and without Liver Fibrosis in a Prospective Study at a Large Urban Medical Center.
J Viral Hepat. 2019 Nov 19. doi: 10.1111/jvh.13234.
PubMed Abstract available

BAJIS S, Grebely J, Hajarizadeh B, Applegate T, et al
Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
J Viral Hepat. 2019 Nov 7. doi: 10.1111/jvh.13233.
PubMed Abstract available

NAYAGAM S, Shimakawa Y, Lemoine M
Mother to child transmission of hepatitis B: What more needs to be done to eliminate it around the world?
J Viral Hepat. 2019 Nov 7. doi: 10.1111/jvh.13231.
PubMed Abstract available

CACCIOLA I, Borgia F, Filomia R, Pitrone C, et al
Outcome of cutaneous psoriasis in hepatitis C virus infected patients treated with Direct Acting Antiviral therapy.
J Viral Hepat. 2019 Nov 7. doi: 10.1111/jvh.13230.
PubMed Abstract available

MCDONALD SA, Pollock KG, Barclay ST, Goldberg DJ, et al
Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis.
J Viral Hepat. 2019 Nov 6. doi: 10.1111/jvh.13232.
PubMed Abstract available

October 2019

CARDOZO EF, Ji D, Lau G, Schinazi RF, et al
Disentangling the life-spans of hepatitis C virus infected cells and intracellular vRNA replication-complexes during direct acting antiviral therapy.
J Viral Hepat. 2019 Oct 31. doi: 10.1111/jvh.13229.
PubMed Abstract available

LUO H, Tan N, Kang Q, Pan J, et al
HBV pgRNA status can reveal the long-term prognoses of chronic hepatitis B patients treated with nucleos(t)ide analogues.
J Viral Hepat. 2019 Oct 31. doi: 10.1111/jvh.13227.
PubMed Abstract available

SAHAKYAN Y, Wong W, Yi Q, Thein HH, et al
Long-term morbidity and mortality in a Canadian post-transfusion hepatitis C cohort: over 15 years of follow-up.
J Viral Hepat. 2019 Oct 26. doi: 10.1111/jvh.13226.
PubMed Abstract available

CARRAT F, Nahon P, Fontaine H, Pol S, et al
Comparing Interferon-free with Interferon-based regimens in HCV patients: Rogers phenomenon and Simpson's paradox.
J Viral Hepat. 2019 Oct 26. doi: 10.1111/jvh.13225.
PubMed Abstract available

MARTIN P, Jadoul M, Pol S
HCV in the Hemodialysis Population: treat now or later?
J Viral Hepat. 2019 Oct 24. doi: 10.1111/jvh.13224.
PubMed Abstract available

LIM TS, Lee JS, Kim BK, Lee HW, et al
An observational study on long-term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate.
J Viral Hepat. 2019 Oct 22. doi: 10.1111/jvh.13222.
PubMed Abstract available

BAIK D, Kim BW, Oh JK, Kim KA, et al
Costs of Viral Hepatitis B in the Republic of Korea, 2002-2015.
J Viral Hepat. 2019 Oct 22. doi: 10.1111/jvh.13219.
PubMed Abstract available

YANES-LANE M, Dussault C, Linthwaite B, Cox J, et al
Using the barriers and facilitators to linkage to HIV care to inform hepatitis C virus (HCV) linkage to care strategies for people released from prison: Findings from a systematic review.
J Viral Hepat. 2019 Oct 22. doi: 10.1111/jvh.13220.
PubMed Abstract available

LYU J, Wang S, He Q, Pan C, et al
Hep B Moms: A cross-sectional study of mother-to-child transmission risk among pregnant Asian American women with chronic hepatitis B in New York City, 2007-2017.
J Viral Hepat. 2019 Oct 22. doi: 10.1111/jvh.13221.
PubMed Abstract available

ZENG Y, Chen S, Fu Y, Wu W, et al
Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.
J Viral Hepat. 2019 Oct 10. doi: 10.1111/jvh.13216.
PubMed Abstract available

DANIEL KE, Saeian K, Rizvi S
Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment.
J Viral Hepat. 2019 Oct 10. doi: 10.1111/jvh.13218.
PubMed Abstract available

RUSSO FP, Zanetto A, Gambato M, Bortoluzzi I, et al
Hepatitis C virus eradication with direct acting antiviral improves insulin resistance.
J Viral Hepat. 2019 Oct 9. doi: 10.1111/jvh.13215.
PubMed Abstract available

September 2019

YANG R, Gui X, Ke H, Xiong Y, et al
Long-term observation on Hepatitis B surface antigen (HBsAg) seroclearance in therapy experienced HIV/HBV co-infected Chinese.
J Viral Hepat. 2019 Sep 30. doi: 10.1111/jvh.13212.
PubMed Abstract available

SHEN K, Yang NS, Huang W, Fitzpatrick TS, et al
A crowdsourced intervention to decrease hepatitis B stigma in men who have sex with men in China: a cohort study.
J Viral Hepat. 2019 Sep 30. doi: 10.1111/jvh.13213.
PubMed Abstract available

PHILLIPS C, Schulkind J, O'Sullivan M, Edelman N, et al
Improving access to care for People Who Inject Drugs: Qualitative evaluation of Project ITTREAT, an integrated community hepatitis C service.
J Viral Hepat. 2019 Sep 30. doi: 10.1111/jvh.13214.
PubMed Abstract available

PAPATHEODORIDI M, Hadziyannis E, Berby F, Zachou K, et al
Predictors of HBsAg loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in non-cirrhotic HBeAg-negative chronic hepatitis B.
J Viral Hepat. 2019 Sep 28. doi: 10.1111/jvh.13211.
PubMed Abstract available

BAKAROZI M, Mavropoulos A, Bogdanos DP, Dalekos GN, et al
Title: p38 mitogen-activated protein kinase impairment of innate immune cells is a characteristic feature of HBeAg-negative chronic hepatitis B.
J Viral Hepat. 2019 Sep 13. doi: 10.1111/jvh.13209.
PubMed Abstract available

RAO H, Song G, Li G, Yang Y, et al
Safety and efficacy of coblopasvir and sofosbuvir in patients with genotype 1, 2, 3, and 6 HCV infections without or with compensated cirrhosis.
J Viral Hepat. 2019 Sep 13. doi: 10.1111/jvh.13208.
PubMed Abstract available

BUCHANAN R, Cooper K, Grellier L, Khakoo SI, et al
The testing of people with any risk factor for Hepatitis C in community pharmacies is cost effective.
J Viral Hepat. 2019 Sep 13. doi: 10.1111/jvh.13207.
PubMed Abstract available

VAN SANTEN DK, Boyd A, Bruisten S, Sonder GJ, et al
Frequent delayed spontaneous seroclearance of hepatitis B virus after incident HBV infection among adult high-risk groups.
J Viral Hepat. 2019 Sep 13. doi: 10.1111/jvh.13205.
PubMed Abstract available

MAK JSM, Lao TT, Leung MBW, Chung CHS, et al
Ovarian HBV replication following ovulation induction in female Hepatitis B carriers undergoing IVF treatment: a prospective observational study.
J Viral Hepat. 2019 Sep 13. doi: 10.1111/jvh.13210.
PubMed Abstract available

SAINZ T, Fernandez McPhee C, Dominguez-Rodriguez S, Hierro L, et al
Longitudinal Evolution Of Vertically HIV/HCV Coinfected Vs HCV Monoinfected Children.
J Viral Hepat. 2019 Sep 13. doi: 10.1111/jvh.13206.
PubMed Abstract available

MILLER LS, Millman AJ, Lom J, Osinubi A, et al
Defining the Hepatitis C Cure Cascade in an Urban Health System Using the Electronic Health Record.
J Viral Hepat. 2019 Sep 10. doi: 10.1111/jvh.13199.
PubMed Abstract available

CHO KS, Sohn W, Lee YC, Chi SA, et al
Use of cyclooygenase inhibitor and the risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nested case-control study using a nationwide population-based data.
J Viral Hepat. 2019 Sep 10. doi: 10.1111/jvh.13201.
PubMed Abstract available

IRELAND G, Simmons R, Hickman M, Harris R, et al
Data linkage to monitor hepatitis C-associated end-stage liver disease and hepatocellular carcinoma inpatient stays in England.
J Viral Hepat. 2019 Sep 10. doi: 10.1111/jvh.13203.
PubMed Abstract available

ARSLAN F
Cytomegalovirus and hepatitis after bone marrow transplantation.
J Viral Hepat. 2019 Sep 10. doi: 10.1111/jvh.13200.
PubMed Abstract available

LAURSEN TL, Siggaard CB, Kazankov K, Sandahl TD, et al
Time-dependent improvement of liver inflammation, fibrosis, and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C.
J Viral Hepat. 2019 Sep 10. doi: 10.1111/jvh.13204.
PubMed Abstract available

HE WQ, Duong MC, Gidding H, MacLachlan J, et al
Trends in chronic hepatitis B prevalence in Australian women by country of birth, 2000 to 2016.
J Viral Hepat. 2019 Sep 9. doi: 10.1111/jvh.13202.
PubMed Abstract available

August 2019

CATLETT B, Lamoury FMJ, Bajis S, Hajarizadeh B, et al
Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: a cohort study.
J Viral Hepat. 2019 Aug 26. doi: 10.1111/jvh.13196.
PubMed Abstract available

LIMOTHAI U, Chuaypen N, Poovorawan K, Chotiyaputta W, et al
Baseline and kinetics of serum HBV RNA predict response to pegylated interferon-based therapy in patients with HBeAg-negative chronic hepatitis B.
J Viral Hepat. 2019 Aug 25. doi: 10.1111/jvh.13195.
PubMed Abstract available

JACKA B, Roy E, Hoj S, Minoyan N, et al
Sexual behaviour as a risk factor for hepatitis C virus infection among people who inject drugs in Montreal, Canada.
J Viral Hepat. 2019 Aug 21. doi: 10.1111/jvh.13194.
PubMed Abstract available

ROSA-HEZODE I, Chousterman M, Costes L, Labourdette C, et al
Cascade of care for migrants tested Hepatitis C antibodies positive in France through a systematic screening program: the PRECAVIR study.
J Viral Hepat. 2019 Aug 21. doi: 10.1111/jvh.13192.
PubMed Abstract available

TSAI MC, Lin CY, Hung CH, Lu SN, et al
Evolution of Renal function under directly acting antivirals treatment for chronic hepatitis C: A real world experience.
J Viral Hepat. 2019 Aug 21. doi: 10.1111/jvh.13193.
PubMed Abstract available

TO WP, Mak LY, Wong DK, Fung J, et al
Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma.
J Viral Hepat. 2019 Aug 16. doi: 10.1111/jvh.13191.
PubMed Abstract available

FUJII H, Enomoto M, Murakami Y, Hagihara A, et al
Last crusade against HCV: Direct-acting antiviral treatment for marginalized populations.
J Viral Hepat. 2019 Aug 14. doi: 10.1111/jvh.13190.
PubMed Abstract available

YIN X
It is too early to evaluate mother-to-child transmission of hepatitis B within 24 hours after delivery.
J Viral Hepat. 2019 Aug 14. doi: 10.1111/jvh.13189.
PubMed Abstract available

TRICKEY A, Fraser H, Lim AG, Walker JG, et al
Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional, and country levels: a modelling study.
J Viral Hepat. 2019 Aug 7. doi: 10.1111/jvh.13187.
PubMed Abstract available

KRAMER J, Wolffram I, Fruh U, Batz O, et al
Laboratory reform counteracts the WHO hepatitis C elimination strategy in Germany.
J Viral Hepat. 2019 Aug 6. doi: 10.1111/jvh.13188.
PubMed Abstract available

LUSIVIKA-NZINGA C, Fontaine H, Dorival C, Simony M, et al
The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C.
J Viral Hepat. 2019 Aug 6. doi: 10.1111/jvh.13186.
PubMed Abstract available

July 2019

SINN DH, Kim SE, Kim BK, Kim JH, et al
The Risk of Hepatocellular Carcinoma Among Chronic Hepatitis B Virus Infected Patients Outside Current Treatment Criteria.
J Viral Hepat. 2019 Jul 22. doi: 10.1111/jvh.13185.
PubMed Abstract available

MASON LMK, Veldhuijzen IK, Duffell E, van Ahee A, et al
Hepatitis B and C testing strategies in healthcare and community settings in the EU/EEA: a systematic review.
J Viral Hepat. 2019 Jul 22. doi: 10.1111/jvh.13182.
PubMed Abstract available

MAISA A, Semple S, Griffiths A, Ngui SL, et al
Risk behaviours of homeless people who inject drugs during an outbreak of hepatitis C, Northern Ireland, 2016-2017.
J Viral Hepat. 2019 Jul 22. doi: 10.1111/jvh.13184.
PubMed Abstract available

MARRONE A, Ciotti M, Rinaldi L, Adinolfi LE, et al
Hepatitis B and C virus infection and risk of hematological malignancies.
J Viral Hepat. 2019 Jul 20. doi: 10.1111/jvh.13183.
PubMed Abstract available

WINETSKY D, Zucker J, Carnevale C, Theodore D, et al
Attitudes, practices and perceived barriers to hepatitis C screening among medical residents at a large urban academic medical center.
J Viral Hepat. 2019 Jul 20. doi: 10.1111/jvh.13181.
PubMed Abstract available

USMAN Z, Mijocevic H, Karimzadeh H, Daumer M, et al
Kinetics of hepatitis B surface antigen quasispecies during REP 2139-Ca therapy in HBeAg positive chronic HBV infection.
J Viral Hepat. 2019 Jul 19. doi: 10.1111/jvh.13180.
PubMed Abstract available

SCHAUER C, van Rijnsoever M, Gane E
Surveillance factors change outcomes in patients with hepatocellular carcinoma due to chronic hepatitis C virus infection in New Zealand.
J Viral Hepat. 2019 Jul 19. doi: 10.1111/jvh.13179.
PubMed Abstract available

GOUNTAS I, Sypsa V, Papatheodoridis G, Paraskevis D, et al
A Hepatitis C outbreak preceded the HIV outbreak among persons who inject drugs in Athens, Greece. Insights from a mathematical modeling study.
J Viral Hepat. 2019 Jul 19. doi: 10.1111/jvh.13178.
PubMed Abstract available

MAXIME G, Mouna L, Coustilleres F, Lemee V, et al
Invasive meningoencephalitis as the first manifestation of hepatitis A.
J Viral Hepat. 2019 Jul 18. doi: 10.1111/jvh.13177.
PubMed Abstract available

MCDONALD GB, Sarmiento JI, Rees-Lui G, Myerson D, et al
Cytomegalovirus hepatitis after bone marrow transplantation: An autopsy study with clinical, histologic, and laboratory correlates.
J Viral Hepat. 2019 Jul 17. doi: 10.1111/jvh.13176.
PubMed Abstract available

READ P, Gilliver R, Kearley J, Lothian R, et al
Treatment Adherence and Support for People who Inject Drugs Taking Direct Acting Antiviral Therapy for Hepatitis C Infection.
J Viral Hepat. 2019 Jul 12. doi: 10.1111/jvh.13175.
PubMed Abstract available

WU J, Guo N, Zhang X, Xiong C, et al
HEV-LFS : a novel scoring model for patients with hepatitis E virus-related liver failure.
J Viral Hepat. 2019 Jul 11. doi: 10.1111/jvh.13174.
PubMed Abstract available

DESHPANDE R, Stepanova M, Golabi P, Brown K, et al
Prevalence, mortality and healthcare utilization among Medicare beneficiaries with Hepatitis C in Hemodialysis units.
J Viral Hepat. 2019 Jul 11. doi: 10.1111/jvh.13173.
PubMed Abstract available

IKEDA H, Watanabe T, Atsukawa M, Toyoda H, et al
Evaluation of 8-Week Glecaprevir/Pibrentasvir Treatment in Direct-acting Antiviral -naive Non-cirrhotic Genotype 1 and 2 HCV Patients in a Real-world Setting in Japan.
J Viral Hepat. 2019 Jul 6. doi: 10.1111/jvh.13170.
PubMed Abstract available

PRONIER C, Fontaine H, Dorival C, Carrat F, et al
Genetic diversity of genotype 6 HCV infections in France: epidemiology and consequences for treatment strategy.
J Viral Hepat. 2019 Jul 5. doi: 10.1111/jvh.13171.
PubMed Abstract available

MENDIZABAL M, Ridruejo E, Ceballos S, Sixto M, et al
The ECHO model proved to be a useful tool to increase clinicians' self-effectiveness for care of patients with Hepatitis C in Argentina.
J Viral Hepat. 2019 Jul 5. doi: 10.1111/jvh.13172.
PubMed Abstract available

XIE Y, Yi W, Zhang L, Lu Y, et al
Evaluation of a logistic regression model for predicting liver necroinflammation in hepatitis B e antigen-negative chronic hepatitis B patients with normal and minimally increased alanine aminotransferase levels.
J Viral Hepat. 2019;26 Suppl 1:42-49.
PubMed Abstract available

LI G, Zhang Q, Yu Y, Qiu C, et al
Histological responses of peginterferon alpha add-on therapy in patients with chronic hepatitis B with advanced liver fibrosis after long-term nucleos(t)ide analog treatment.
J Viral Hepat. 2019;26 Suppl 1:50-58.
PubMed Abstract available

DUAN BW, Tian LT, Lin DD, Zhang J, et al
Long-term consequences of stopping HBIG and/or nucleotide analogues in liver transplant recipients administered hepatitis B vaccination to prevent HBV reinfection.
J Viral Hepat. 2019;26 Suppl 1:85-89.
PubMed Abstract available

ZHANG Q, Li G, Yu Y, Qiu C, et al
Histological response to combination therapy with nucleos(t)ide analogs and peginterferon alpha in treatment-naive chronic hepatitis B patients.
J Viral Hepat. 2019;26 Suppl 1:59-68.
PubMed Abstract available

REN H
On the way towards the eradication of chronic hepatitis B.
J Viral Hepat. 2019;26 Suppl 1:3-4.
PubMed

FAN H, Lin L, Jia S, Xie M, et al
Interferon alpha treatment leads to a high rate of hepatitis B surface antigen seroconversion in Chinese children with chronic hepatitis B.
J Viral Hepat. 2019;26 Suppl 1:77-84.
PubMed Abstract available

LIU Y, Li H, Yan X, Wei J, et al
Long-term efficacy and safety of peginterferon in the treatment of children with HBeAg-positive chronic hepatitis B.
J Viral Hepat. 2019;26 Suppl 1:69-76.
PubMed Abstract available

REN H, Huang Y
Effects of pegylated interferon-alpha based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B.
J Viral Hepat. 2019;26 Suppl 1:5-31.
PubMed Abstract available

CHEN H, Luo S, Lu W, Chen Z, et al
Serum protein expression patterns in detecting a new viral protein in HBeAg-negative chronic hepatitis B.
J Viral Hepat. 2019;26 Suppl 1:90-97.
PubMed Abstract available

LI MH, Yi W, Zhang L, Lu Y, et al
Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy.
J Viral Hepat. 2019;26 Suppl 1:32-41.
PubMed Abstract available

June 2019

PELEG N, Issachar A, Sneh-Arbib O, Cohen-Naftaly M, et al
Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virologic response.
J Viral Hepat. 2019 Jun 27. doi: 10.1111/jvh.13167.
PubMed Abstract available

CHUNG S, Roh EY, Park B, Lee Y, et al
GWAS identifying HLA-DPB1 gene variants associated with responsiveness to hepatitis B virus vaccination in Koreans: Independent association of HLA-DPB1*04:02 possessing rs1042169 G - rs9277355 C - rs9277356 A.
J Viral Hepat. 2019 Jun 27. doi: 10.1111/jvh.13168.
PubMed Abstract available

VILLANI R, Monami M, Di Cosimo F, Fioravanti G, et al
Direct-Acting antivirals for HCV treatment in older patients: a systematic review and meta-analysis.
J Viral Hepat. 2019 Jun 27. doi: 10.1111/jvh.13169.
PubMed Abstract available

ASSELAH T, Shafran SD, Bourgeois S, Lai CL, et al
Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4, and 6 infection.
J Viral Hepat. 2019 Jun 19. doi: 10.1111/jvh.13159.
PubMed Abstract available

LU M, Wu KH, Li J, Moorman AC, et al
Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure.
J Viral Hepat. 2019 Jun 13. doi: 10.1111/jvh.13162.
PubMed Abstract available

RAGONNET-CRONIN M, Hostager R, Hedskog C, Osinusi A, et al
HIV co-infection is associated with increased transmission risk in patients with chronic hepatitis C virus.
J Viral Hepat. 2019 Jun 13. doi: 10.1111/jvh.13160.
PubMed Abstract available

VERCOUTER AS, Van Houtte F, Verhoye L, Gonzalez Fraile I, et al
Hepatitis E virus prevalence in Flemish blood donors.
J Viral Hepat. 2019 Jun 13. doi: 10.1111/jvh.13161.
PubMed Abstract available

LIU J, Wang J, Yan T, Du D, et al
Efficacy and safety of Telbivudine and Tenofovir disoproxil fumarate in preventing hepatitis B vertical transmission: a real-life practice.
J Viral Hepat. 2019 Jun 8. doi: 10.1111/jvh.13156.
PubMed Abstract available

DEGASPERI E, Galmozzi E, Facchetti F, Farina E, et al
TLL1 Variants do not predict hepatocellular carcinoma development in hcv cirrhotic patients treated with direct-acting antivirals.
J Viral Hepat. 2019 Jun 8. doi: 10.1111/jvh.13155.
PubMed Abstract available

May 2019

RIDRUEJO E, Cheinquer H, Marciano S, Mendizabal M, et al
B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin.
J Viral Hepat. 2019 May 29. doi: 10.1111/jvh.13148.
PubMed Abstract available

WILLEMSE S, Smit C, Sogni P, Sarcletti M, et al
Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV-patients with cirrhosis.
J Viral Hepat. 2019 May 28. doi: 10.1111/jvh.13146.
PubMed Abstract available

VAN CAMPENHOUT MJH, Rijckborst V, Brouwer WP, van Oord GW, et al
Hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B.
J Viral Hepat. 2019 May 28. doi: 10.1111/jvh.13117.
PubMed Abstract available

CLARKE WT, Miranda J, Neidich E, Hudock R, et al
Metabolic Syndrome and Liver Steatosis occur at lower body mass index in US Asian patients with Chronic Hepatitis B.
J Viral Hepat. 2019 May 28. doi: 10.1111/jvh.13147.
PubMed Abstract available

NANGIA G, Borges K, Reddy KR
Use of HCV-infected organs in solid organ transplantation: An ethical challenge but plausible option.
J Viral Hepat. 2019 May 20. doi: 10.1111/jvh.13130.
PubMed Abstract available

LAWITZ E, Gane E, Feld JJ, Buti M, et al
Efficacy and Safety of a Two-Drug Direct-Acting Antiviral Agent Regimen Ruzasvir 180 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults with Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, 5, or 6.
J Viral Hepat. 2019 May 20. doi: 10.1111/jvh.13132.
PubMed Abstract available

ATSAMA MA, Marchio A, Bivigou-Mboumba B, Noah Noah D, et al
Enrichment in selected genotypes, basal core and precore mutations of hepatitis B virus in patients with hepatocellular carcinoma in Cameroon.
J Viral Hepat. 2019 May 20. doi: 10.1111/jvh.13131.
PubMed Abstract available

HLAING NKT, Nangia G, Tun KT, Lin S, et al
High Sustained Virologic Response in Genotypes 3 and 6 with Generic NS5A Inhibitor and Sofosbuvir regimens in chronic HCV in Myanmar.
J Viral Hepat. 2019 May 18. doi: 10.1111/jvh.13133.
PubMed Abstract available

LHOMME S, Gallian P, Dimeglio C, Assal A, et al
Viral load and clinical manifestations of hepatitis E virus genotype 3 infections.
J Viral Hepat. 2019 May 16. doi: 10.1111/jvh.13128.
PubMed Abstract available

BERGLOV A, Hallager S, Weis N
Hepatitis E during pregnancy: maternal and fetal case-fatality rates and adverse outcomes - a systematic review.
J Viral Hepat. 2019 May 16. doi: 10.1111/jvh.13129.
PubMed Abstract available

ZHAO M, Zou H, Chen Y, Zheng S, et al
Efficacy of antepartum administration of Hepatitis B immunoglobulin in preventing mother-to-child transmission of Hepatitis B virus.
J Viral Hepat. 2019 May 14. doi: 10.1111/jvh.13123.
PubMed Abstract available

VAN DAMME P, Dionne M, Leroux-Roels G, Van Der Meeren O, et al
Persistence of HBsAg-specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults.
J Viral Hepat. 2019 May 14. doi: 10.1111/jvh.13125.
PubMed Abstract available

MOORE MS, Greene SK, Bocour A, Brown CM, et al
Comprehensive nationwide chronic hepatitis C surveillance is necessary for accurate state-level prevalence estimates.
J Viral Hepat. 2019 May 13. doi: 10.1111/jvh.13124.
PubMed Abstract available

NING Q, Wu D, Wang G, Ren H, et al
Roadmap to Functional Cure of Chronic Hepatitis B: an expert consensus.
J Viral Hepat. 2019 May 13. doi: 10.1111/jvh.13126.
PubMed Abstract available

MORALES-ARRAEZ D, Alonso-Larruga A, Diaz-Flores F, Garcia Dopico JA, et al
Predictive factors for not undergoing RNA testing in patients found to have hepatitis C serology and impact of an automatic alert.
J Viral Hepat. 2019 May 11. doi: 10.1111/jvh.13122.
PubMed Abstract available

GHOSH A, Mondal RK, Romani S, Bagchi S, et al
Persistent Gamma Delta-T cell Dysfunction in Chronic HCV Infection Despite Direct Acting Antiviral Therapy Induced Cure.
J Viral Hepat. 2019 May 9. doi: 10.1111/jvh.13121.
PubMed Abstract available

LITWIN AH, Drolet M, Nwankwo C, Torrens M, et al
Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C-SCOPE Study.
J Viral Hepat. 2019 May 9. doi: 10.1111/jvh.13119.
PubMed Abstract available

LIU W, Liang H, Wang S, Wu C, et al
Transcriptional response of USP18 predicts treatment outcomes of interferon-alpha in HBeAg-positive chronic hepatitis B patients.
J Viral Hepat. 2019 May 9. doi: 10.1111/jvh.13120.
PubMed Abstract available

JENG WJ, Yang HI
Discrepant range of sPD-1 in different studies of Chronic hepatitis B.
J Viral Hepat. 2019 May 4. doi: 10.1111/jvh.13102.
PubMed Abstract available

ZHOU L, Li X, Huang X, Chen L, et al
Reply to the letter by Jeng et al. 'Discrepant range of sPD-1 in different studies of Chronic hepatitis B'.
J Viral Hepat. 2019 May 4. doi: 10.1111/jvh.13118.
PubMed Abstract available

April 2019

BELPERIO PS, Shahoumian TA, Loomis TP, Backus LI, et al
Real World Effectiveness of Sofosbuvir/velpatasvir/voxilaprevir in 573 Direct-Acting Antiviral Experienced Hepatitis C Patients.
J Viral Hepat. 2019 Apr 22. doi: 10.1111/jvh.13115.
PubMed Abstract available

DVORY-SOBOL H, Han B, Lu J, Yu M, et al
In Vitro Resistance Profile of Hepatitis C Virus NS5A Inhibitor Velpatasvir in Genotypes 1 to 6.
J Viral Hepat. 2019 Apr 22. doi: 10.1111/jvh.13116.
PubMed Abstract available

BAJIS S, Grebely J, Cooper L, Smith J, et al
Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study.
J Viral Hepat. 2019 Apr 13. doi: 10.1111/jvh.13112.
PubMed Abstract available

INDOLFI G, Bailey H, Serranti D, Giaquinto C, et al
Treatment and Monitoring of Children with Chronic Hepatitis C in the Pre-DAA Era: a European Survey of 38 Paediatric Specialists.
J Viral Hepat. 2019 Apr 13. doi: 10.1111/jvh.13111.
PubMed Abstract available

KARNSAKUL W, Schwarz KB
Management of HCV in Children in the Era of DAA's.
J Viral Hepat. 2019 Apr 13. doi: 10.1111/jvh.13113.
PubMed Abstract available

POORDAD F, Sedghi S, Pockros PJ, Ravendhran N, et al
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
J Viral Hepat. 2019 Apr 13. doi: 10.1111/jvh.13109.
PubMed Abstract available

BACK D, Belperio P, Bondin M, Negro F, et al
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection and Psychiatric Disorders: An Integrated Analysis.
J Viral Hepat. 2019 Apr 12. doi: 10.1111/jvh.13110.
PubMed Abstract available

DI BISCEGLIE AM, King WC, Lisker-Melman M, Khalili M, et al
Age, race and viral genotype are associated with the prevalence of Hepatitis B e antigen in children and adults with chronic Hepatitis B.
J Viral Hepat. 2019 Apr 11. doi: 10.1111/jvh.13104.
PubMed Abstract available

TAMAKI N, Higuchi M, Kurosaki M, Kirino S, et al
Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct acting antivirals.
J Viral Hepat. 2019 Apr 11. doi: 10.1111/jvh.13103.
PubMed Abstract available

CARABALLO CORTES K, Osuch S, Perlejewski K, Pawelczyk A, et al
Expression of programmed cell death protein 1 (PD-1) and T cell immunoglobulin and mucin domain-containing molecule-3 (Tim-3) on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus (HCV) infection and in subjec
J Viral Hepat. 2019 Apr 10. doi: 10.1111/jvh.13108.
PubMed Abstract available

WEI L, Pavlovic V, Bansal AT, Chen X, et al
Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B.
J Viral Hepat. 2019 Apr 10. doi: 10.1111/jvh.13107.
PubMed Abstract available

WEN B, Zhang J, Liu W, Tang P, et al
HBV coinfection with HCV alters circulating Tfh cell distribution and impairs HCV neutralizing antibody responses.
J Viral Hepat. 2019 Apr 10. doi: 10.1111/jvh.13106.
PubMed Abstract available

March 2019

HAGA H, Saito T, Okumoto K, Tomita K, et al
Incidence of development of hepatocellular carcinoma in Japanese patients infected with hepatitis B virus are equivalent between genotype B and C in long term.
J Viral Hepat. 2019 Mar 28. doi: 10.1111/jvh.13099.
PubMed Abstract available

DE LA TORRE A, Ahmad M, Ayoub F, Korogodsky M, et al
Electronic Health Record Year and Country of Birth Testing and Patient Navigation to Increase Diagnosis of Chronic Viral Hepatitis.
J Viral Hepat. 2019 Mar 28. doi: 10.1111/jvh.13098.
PubMed Abstract available

SONNEVELD MJ, Van Oord GW, van Campenhout MJ, de Man RA, et al
Relationship between hepatitis B Core related antigen levels and sustained HBeAg seroconversion in patients treated with nucleo(s)tide analogues.
J Viral Hepat. 2019 Mar 21. doi: 10.1111/jvh.13097.
PubMed Abstract available

SIMMONS R, Ireland G, Ijaz S, Ramsay M, et al
Causes of death among persons diagnosed with hepatitis C infection in the pre and post DAA era in England: a record linkage study.
J Viral Hepat. 2019 Mar 21. doi: 10.1111/jvh.13096.
PubMed Abstract available

MAK LY, Seto WK, Hui RW, Fung J, et al
Fibrosis evolution in chronic hepatitis B E-antigen negative patients across a 10-year interval.
J Viral Hepat. 2019 Mar 21. doi: 10.1111/jvh.13095.
PubMed Abstract available

February 2019

WILSON EC, Turner C, Lin J, McFarland W, et al
Hepatitis C seroprevalence and engagement in related care and treatment among transwomen.
J Viral Hepat. 2019 Feb 27. doi: 10.1111/jvh.13089.
PubMed Abstract available

PLATT L, Stengel CM, Nkurunziza M, Muhangi D, et al
Assessing risk of HIV and hepatitis C among people who inject drugs in East Africa: findings from a rapid assessment.
J Viral Hepat. 2019 Feb 27. doi: 10.1111/jvh.13088.
PubMed Abstract available

MARTINEZ MG, Testoni B, Zoulim F
Biological basis for functional cure of chronic hepatitis B.
J Viral Hepat. 2019 Feb 25. doi: 10.1111/jvh.13090.
PubMed Abstract available

TURKOVA A, Volynets GV, Crichton S, Skvortsova TA, et al
Advanced liver disease in Russian children and adolescents with chronic hepatitis C.
J Viral Hepat. 2019 Feb 25. doi: 10.1111/jvh.13093.
PubMed Abstract available

DORE GJ
HCV reinfection as a positive indication of high-risk population treatment access.
J Viral Hepat. 2019 Feb 25. doi: 10.1111/jvh.13092.
PubMed Abstract available

LIM SG, Agcaoili J, De Souza NNA, Chan E, et al
Therapeutic Vaccination for Chronic Hepatitis B: A Systematic Review and Meta-analysis.
J Viral Hepat. 2019 Feb 23. doi: 10.1111/jvh.13085.
PubMed Abstract available

LATHAM NH, Pedrana A, Doyle JS, Howell J, et al
Community-based, point-of-care hepatitis C testing: perspectives and preferences of people who inject drugs.
J Viral Hepat. 2019 Feb 23. doi: 10.1111/jvh.13087.
PubMed Abstract available

VANOPDORP JR, Ferrentino N, Strader DB, Lidofsky SD, et al
Utility of laboratory monitoring during hepatitis C treatment with ribavirin-free direct acting antiviral regimens.
J Viral Hepat. 2019 Feb 23. doi: 10.1111/jvh.13083.
PubMed Abstract available

KARIMZADEH H, Usman Z, Frishman D, Roggendorf M, et al
Genetic diversity of hepatitis D virus genotype 1 in Europe allows classification into subtypes.
J Viral Hepat. 2019 Feb 23. doi: 10.1111/jvh.13086.
PubMed Abstract available

VAN HEES S, Chi H, Hansen B, Bourgeois S, et al
Sustained off-treatment viral control is associated with high Hepatitis B Surface Antigen seroclearance rates in Caucasian patients with Nucleos(t)ide Analogue induced HBeAg seroconversion.
J Viral Hepat. 2019 Feb 23. doi: 10.1111/jvh.13084.
PubMed Abstract available

LOMBARDI A, Rossotti R, Moioli MC, Merli M, et al
The impact of HIV infection and MSM status on hepatitis A infection: the experience of two tertiary centres in Northern Italy during the 2017 outbreak and in the 2009-2016 period.
J Viral Hepat. 2019 Feb 22. doi: 10.1111/jvh.13082.
PubMed Abstract available

IDILMAN R, Demir M, Aladag M, Erol C, et al
Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort.
J Viral Hepat. 2019 Feb 11. doi: 10.1111/jvh.13075.
PubMed Abstract available

FERENCI P, Bourgeois S, Buggisch P, Norris S, et al
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observation
J Viral Hepat. 2019 Feb 10. doi: 10.1111/jvh.13080.
PubMed Abstract available

GIADANS CG, Rios DA, Ameigeiras B, Pietrantonio AM, et al
Chronic Hepatitis B: The interplay between intrahepatic lymphocyte population and viral antigens in relation to liver damage.
J Viral Hepat. 2019 Feb 9. doi: 10.1111/jvh.13078.
PubMed Abstract available

PALAZZO D, Biliotti E, Esvan R, Volpicelli L, et al
Vitamin D deficiency and health-related quality of life in chronic hepatitis C.
J Viral Hepat. 2019 Feb 9. doi: 10.1111/jvh.13076.
PubMed Abstract available

LAWITZ E, Poordad F, Anderson LJ, Vesay M, et al
Efficacy and Safety of Ruzasvir 60 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection.
J Viral Hepat. 2019 Feb 9. doi: 10.1111/jvh.13079.
PubMed Abstract available

SHYU YC, Huang TS, Chien CH, Yeh CT, et al
Diabetes poses a higher risk of hepatocellular carcinoma and mortality in patients with chronic hepatitis B: a population-based cohort study.
J Viral Hepat. 2019 Feb 9. doi: 10.1111/jvh.13077.
PubMed Abstract available

January 2019

BLADOWSKA J, Pawlowski T, Fleischer-Stepniewska K, Knysz B, et al
Interferon-free Therapy as the Cause of White Matter Tracts and Cerebral Perfusion Recovery in Patients with Chronic Hepatitis C.
J Viral Hepat. 2019 Jan 31. doi: 10.1111/jvh.13069.
PubMed Abstract available

KRANIDIOTI H, Manolakopoulos S, Kontos G, Breen MS, et al
Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg negative chronic hepatitis B.
J Viral Hepat. 2019 Jan 31. doi: 10.1111/jvh.13068.
PubMed Abstract available

JACK K, Thomson BJ, Irving WL
Testing for hepatitis C virus infection in UK Prisons: what actually happens?
J Viral Hepat. 2019 Jan 31. doi: 10.1111/jvh.13071.
PubMed Abstract available

CHEN WC, Wei CK, Lee JC
MicroRNA-let-7c suppresses hepatitis C virus replication by targeting Bach1 for induction of heme oxygenase-1 expression.
J Viral Hepat. 2019 Jan 31. doi: 10.1111/jvh.13072.
PubMed Abstract available

HARRIS RJ, Harris H, Mandal S, Ramsay M, et al
Monitoring the hepatitis C epidemic in England and evaluating intervention scale-up using routinely collected data.
J Viral Hepat. 2019 Jan 21. doi: 10.1111/jvh.13063.
PubMed Abstract available

RUANE P, Strasser SI, Gane EJ, Hyland RH, et al
Sofosbuvir/Velpatasvir/Voxilaprevir for Patients with HCV Who Previously Received a Sofosbuvir/Velpatasvir-Containing Regimen: Results from a Retreatment Study.
J Viral Hepat. 2019 Jan 21. doi: 10.1111/jvh.13067.
PubMed Abstract available

MAHALE P, Aka P, Chen X, Pfeiffer RM, et al
Hepatitis D virus infection, cirrhosis, and hepatocellular carcinoma in The Gambia.
J Viral Hepat. 2019 Jan 20. doi: 10.1111/jvh.13065.
PubMed Abstract available

RIVERO-JUAREZ A, Jarilla-Fernandez M, Frias M, Madrigal-Sanchez E, et al
Hepatitis e virus in spanish donors and the necessity for screening.
J Viral Hepat. 2019 Jan 19. doi: 10.1111/jvh.13064.
PubMed Abstract available

GIROMETTI N, Devitt E, Phillips J, Nelson M, et al
High rates of unprotected anal sex and use of generic direct-acting antivirals in a cohort of MSM with acute HCV infection.
J Viral Hepat. 2019 Jan 19. doi: 10.1111/jvh.13066.
PubMed Abstract available

NARAYANAN S, Abutaleb A, Sherman KE, Kottilil S, et al
Clinical features and determinants of chronicity in hepatitis e virus infection.
J Viral Hepat. 2019 Jan 12. doi: 10.1111/jvh.13059.
PubMed Abstract available

XU R, Yu Y, Leitch ECM, Wang M, et al
HCV genotype 6 prevalence, spontaneous clearance and diversity amongst elderly members of the Li ethnic minority in Baisha County, China.
J Viral Hepat. 2019 Jan 10. doi: 10.1111/jvh.13062.
PubMed Abstract available

KIM HS, Yang JD, El-Serag HB, Kanwal F, et al
Awareness of Chronic Viral Hepatitis in the United States: An Update from National Health and Nutrition Examination Survey.
J Viral Hepat. 2019 Jan 10. doi: 10.1111/jvh.13060.
PubMed Abstract available

KONG Y, Sun Y, Zhou J, Wu X, et al
Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir.
J Viral Hepat. 2019 Jan 9. doi: 10.1111/jvh.13058.
PubMed Abstract available

December 2018

ZHOU L, Li X, Huang X, Chen L, et al
Soluble Programmed Death-1 Is a Useful Indicator for Inflammatory and Fibrosis Severity in Chronic Hepatitis B.
J Viral Hepat. 2018 Dec 22. doi: 10.1111/jvh.13055.
PubMed Abstract available

RODRIGO C, Leung P, Lloyd AR, Bull RA, et al
Genomic variability of within-host hepatitis C variants in acute infection.
J Viral Hepat. 2018 Dec 22. doi: 10.1111/jvh.13051.
PubMed Abstract available

FONG TL, Lee BT, Tien A, Chang M, et al
Improvement of Bone Mineral Density and Markers of Proximal Renal Tubular Function in Chronic Hepatitis B Patients Switched from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide.
J Viral Hepat. 2018 Dec 21. doi: 10.1111/jvh.13053.
PubMed Abstract available

DI LELLO FA, Ridruejo E, Martinez AP, Perez PS, et al
Molecular epidemiology of hepatitis b virus mutants associated with vaccine-escape, drug-resistance and diagnosis failure.
J Viral Hepat. 2018 Dec 21. doi: 10.1111/jvh.13052.
PubMed Abstract available

LOGGI E, Vukotic R, Conti F, Grandini E, et al
Serum Hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative Chronic Hepatitis B.
J Viral Hepat. 2018 Dec 21. doi: 10.1111/jvh.13054.
PubMed Abstract available

RAMACHANDRAN J, Budd S, Slattery H, Muller K, et al
Hepatitis C virus infection in Australian psychiatric in-patients: a multicenter study of seroprevalence, risk factors and treatment experience.
J Viral Hepat. 2018 Dec 21. doi: 10.1111/jvh.13056.
PubMed Abstract available

HENGST J, Klein AL, Lunemann S, Deterding K, et al
Role of soluble inflammatory mediators and different immune cell populations in early control of symptomatic acute hepatitis C virus infection.
J Viral Hepat. 2018 Dec 8. doi: 10.1111/jvh.13050.
PubMed Abstract available

MARCANTONIO C, Pezzotti P, Bruni R, Taliani G, et al
Incidence of hepatitis E virus infection among blood donors in a high endemic area of Central Italy.
J Viral Hepat. 2018 Dec 7. doi: 10.1111/jvh.13049.
PubMed Abstract available

POURMARZI D, Hall L, Hepworth J, Smirnov A, et al
Clinical effectiveness, cost effectiveness and acceptability of community-based treatment of Hepatitis C Virus infection: a mixed method systematic review.
J Viral Hepat. 2018 Dec 5. doi: 10.1111/jvh.13045.
PubMed Abstract available

LEE SS, Kim CY, Kim BR, Cha RR, et al
Hepatitis C virus genotype 3 was associated with the development of hepatocellular carcinoma in Korea.
J Viral Hepat. 2018 Dec 5. doi: 10.1111/jvh.13047.
PubMed Abstract available

RAUWOLF K, Herbruggen H, Zollner S, Thorer H, et al
Durable control of Hepatitis C through interferon-free antiviral combination therapy immediately prior to allogeneic hematopoietic stem cell transplantation.
J Viral Hepat. 2018 Dec 5. doi: 10.1111/jvh.13046.
PubMed Abstract available

November 2018

HOLMES JA, Carlton-Smith C, Kim AY, Dumas EO, et al
Dynamic Changes in Innate Immune Responses During Direct Acting Antiviral Therapy for HCV Infection.
J Viral Hepat. 2018 Nov 19. doi: 10.1111/jvh.13041.
PubMed Abstract available

MIJOCEVIC H, Karimzadeh H, Seebach J, Usman Z, et al
Variants of hepatitis B virus surface antigen observed during therapy with nucleic acid polymer REP 2139-Ca have no influence on treatment outcome and its detection by diagnostic assays.
J Viral Hepat. 2018 Nov 19. doi: 10.1111/jvh.13044.
PubMed Abstract available

KAPILA N, Flocco G, Al Khalloufi K, Zervos XB, et al
Transplantation of kidneys from HCV viremic donors to HCV viremic recipients followed by early direct acting anti-viral therapy without ribavirin.
J Viral Hepat. 2018 Nov 18. doi: 10.1111/jvh.13042.
PubMed Abstract available

BUTT ZA, Mak S, Gesink D, Gilbert M, et al
Applying core theory and spatial analysis to identify Hepatitis C Virus infection 'core areas' in British Columbia, Canada.
J Viral Hepat. 2018 Nov 17. doi: 10.1111/jvh.13043.
PubMed Abstract available

SCHULKIND J, Stephens B, Ahmad F, Johnston L, et al
High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme.
J Viral Hepat. 2018 Nov 13. doi: 10.1111/jvh.13035.
PubMed Abstract available

FLAMM S, Mutimer D, Asatryan A, Wang S, et al
Glecaprevir/Pibrentasvir in Patients with Chronic HCV Genotype 3 Infection: An Integrated Phase 2/3 Analysis.
J Viral Hepat. 2018 Nov 12. doi: 10.1111/jvh.13038.
PubMed Abstract available

GILL US, Kennedy PTF
The impact of currently licensed therapies on viral and immune responses in Chronic Hepatitis B: considerations for future novel therapeutics.
J Viral Hepat. 2018 Nov 11. doi: 10.1111/jvh.13040.
PubMed Abstract available

SONG J, Yang F, Wang S, Tikande S, et al
Efficacy and safety of antiviral treatment on blocking the mother-to-child transmission of hepatitis B virus: a meta-analysis.
J Viral Hepat. 2018 Nov 11. doi: 10.1111/jvh.13036.
PubMed Abstract available

SERFATY L, Jacobson I, Rockstroh J, Altice FL, et al
The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: an integrated analysis.
J Viral Hepat. 2018 Nov 9. doi: 10.1111/jvh.13037.
PubMed Abstract available

YOUNG K, Liu B, Bhuket T, Gish RG, et al
Improved Liver Transplant Waitlist Mortality and Lower Risk of Disease Progression Among Chronic Hepatitis C Patients Awaiting Liver Transplantation After the Introduction of Direct Acting Antiviral Therapies in the United States.
J Viral Hepat. 2018 Nov 9. doi: 10.1111/jvh.13039.
PubMed Abstract available

ORR C, Aartun J, Masur H, Kottilil S, et al
Characterization of Changes in Intrahepatic Immune Cell Populations During HCV Treatment with Sofosbuvir and Ribavirin.
J Viral Hepat. 2018 Nov 1. doi: 10.1111/jvh.13034.
PubMed Abstract available

YOUNOSSI Z, Papatheodoridis G, Cacoub P, Negro F, et al
The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease.
J Viral Hepat. 2018;25 Suppl 3:6-14.
PubMed Abstract available

October 2018

BRICHLER S, Nahon P, Zoulim F, Layese R, et al
Non-virological factors are drivers of Hepatocellular Carcinoma in virosuppressed Hepatitis B cirrhosis: results of ANRS CO12 CirVir cohort.
J Viral Hepat. 2018 Oct 31. doi: 10.1111/jvh.13029.
PubMed Abstract available

DONG XQ, Wu Z, Zhao H, Wang GQ, et al
Evaluation and Comparison of Thirty Non-invasive Models for Diagnosing Liver Fibrosis in Chinese Hepatitis B Patients.
J Viral Hepat. 2018 Oct 31. doi: 10.1111/jvh.13031.
PubMed Abstract available

WU DB, Jiang W, Wang YH, Chen B, et al
Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in southwest China: real-world experience of a retrospective study.
J Viral Hepat. 2018 Oct 31. doi: 10.1111/jvh.13033.
PubMed Abstract available

WU Z, Dong X, Wang G, Zhao H, et al
Clinical noninvasive markers for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase less than two times upper limit of normal.
J Viral Hepat. 2018 Oct 31. doi: 10.1111/jvh.13030.
PubMed Abstract available

ABDEL GHAFFAR TY, Naghi SE, Gawad MA, Helmy S, et al
Safety and Efficacy of Combined Sofosbuvir/Daclatasvir Treatment of Children and Adolescents with Chronic Hepatitis C Genotype 4.
J Viral Hepat. 2018 Oct 31. doi: 10.1111/jvh.13032.
PubMed Abstract available

HUANG J, Yin P, Zhang L
COPII cargo claudin-12 promotes hepatitis C virus entry.
J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13026.
PubMed Abstract available

SARKAR M, Lai JC, Sawinski D, Zeigler TE, et al
Sex Hormone Levels by Presence and Severity of Cirrhosis in Women With Chronic Hepatitis C Virus (HCV) Infection.
J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13027.
PubMed Abstract available

CHEVALIEZ S, Rodriguez C, Poiteau L, Soulier A, et al
Primary Resistance of Hepatitis B Virus to Nucleoside and Nucleotide Analogues.
J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13025.
PubMed Abstract available

WANG M, Ping Y, Li Z, Li J, et al
Polarization of granulocytic myeloid-derived suppressor cells by hepatitis C core protein is mediated via IL-10/STAT3 signaling.
J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13024.
PubMed Abstract available

VAZIRI A, Gimson A, Agarwal K, Aldersley M, et al
Liver transplant listing for hepatitis C associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct acting antiviral therapy.
J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13022.
PubMed Abstract available

GIRARDIN F, Hearmon N, Negro F, Eddowes L, et al
Increasing Hepatitis C Virus Screening in People Who Inject Drugs in Switzerland Using Rapid Antibody Saliva and Dried Blood Spot Testing: a Cost-Effectiveness Analysis.
J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13023.
PubMed Abstract available

KNOP V, Hofmann WP, Buggisch P, Klinker H, et al
Estimation of liver fibrosis by non-commercial serum markers in comparison to transient elastography in patients with chronic hepatitis C virus infection receiving direct acting antiviral treatment.
J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13021.
PubMed Abstract available

MOREY S, Hamoodi A, Jones D, Young T, et al
Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine.
J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13017.
PubMed Abstract available

GOUTZAMANIS S, Doyle J, Higgs P, Hellard M, et al
Improving hepatitis C direct-acting antiviral access and uptake: a role for patient-reported outcomes and lived-experience.
J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13020.
PubMed Abstract available

ASGARI S, Chaturvedi N, Scepanovic P, Hammer C, et al
Human genomics of acute liver failure due to hepatitis B virus infection: an exome sequencing study in liver transplant recipients.
J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13019.
PubMed Abstract available

MCLEOD A, Weir A, Hutchinson SJ, Goldberg DJ, et al
Hepatitis C test uptake among historic blood transfusion recipients following media coverage of the Penrose Inquiry and an awareness-raising campaign.
J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13016.
PubMed Abstract available

JAYASUNDARA D, Hui BB, Regan DG, Heywood AE, et al
Modelling the decline and future of hepatitis A transmission in Australia.
J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13018.
PubMed Abstract available

September 2018

OU G, Liu X, Yang L, Yu H, et al
Relationship between HLA-DPA1 mRNA expression and susceptibility to hepatitis B.
J Viral Hepat. 2018 Sep 29. doi: 10.1111/jvh.13012.
PubMed Abstract available

JOO EJ, Chang Y, Yeom JS, Cho YK, et al
Chronic Hepatitis B Virus Infection and Risk of Dyslipidemia: A Cohort Study.
J Viral Hepat. 2018 Sep 29. doi: 10.1111/jvh.13014.
PubMed Abstract available

KWON JA, Dore GJ, Grebely J, Hajarizadeh B, et al
Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: a modeling study.
J Viral Hepat. 2018 Sep 29. doi: 10.1111/jvh.13013.
PubMed Abstract available

HERNANDEZ-CONDE M, Fernandez I, Perello C, Gallego A, et al
Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: results from the Spanish HEPA-C real-world cohort.
J Viral Hepat. 2018 Sep 28. doi: 10.1111/jvh.13008.
PubMed Abstract available

MALAGUTI A, Sani F, Stephens BP, Ahmad F, et al
Change in injecting behaviour among people treated for hepatitis C virus: the role of intimate partnerships.
J Viral Hepat. 2018 Sep 27. doi: 10.1111/jvh.13009.
PubMed Abstract available

XIA Y, Pan W, Ke X, Skibbe K, et al
Differential escape of HCV from CD8(+) T cell selection pressure between China and Germany depends on the presenting HLA class I molecule.
J Viral Hepat. 2018 Sep 27. doi: 10.1111/jvh.13011.
PubMed Abstract available

MIAO Z, Zhang S, Ma Z, Hakim MS, et al
Recombinant identification, molecular classification and proposed reference genomes for hepatitis delta virus.
J Viral Hepat. 2018 Sep 27. doi: 10.1111/jvh.13010.
PubMed Abstract available

LIU Z, Chen X, Zhang T
Reply to "The epidemiology of hepatitis B virus infection in China".
J Viral Hepat. 2018 Sep 21. doi: 10.1111/jvh.13007.
PubMed Abstract available

MACIAS J, Tellez F, Rivero-Juarez A, Palacios R, et al
Early emergence of opportunistic infections after starting direct acting antiviral drugs in HIV/HCV coinfected patients.
J Viral Hepat. 2018 Sep 10. doi: 10.1111/jvh.13003.
PubMed Abstract available

LIN SYC, Magalis BR, Salemi M, Liu HF, et al
Origin and Dissemination of Hepatitis B Virus Genotype C in East Asia Revealed by Phylodynamic Analysis and Historical Correlates.
J Viral Hepat. 2018 Sep 10. doi: 10.1111/jvh.13006.
PubMed Abstract available

ZHAO H
The epidemiology of hepatitis B virus infection in China.
J Viral Hepat. 2018 Sep 10. doi: 10.1111/jvh.13004.
PubMed Abstract available

IWAMOTO M, Calzia A, Dublineau A, Rouet F, et al
Field evaluation of GeneXpert((R)) (Cepheid) HCV performance for RNA quantification in a Genotype 1 and 6 predominant patient population in Cambodia.
J Viral Hepat. 2018 Sep 10. doi: 10.1111/jvh.13002.
PubMed Abstract available

BIANCHI FP, Gallone MS, Gallone MF, Larocca AMV, et al
HBV seroprevalence after 25 years of universal mass vaccination and management of non-responders to the anti-Hepatitis B vaccine: an Italian study among medical students.
J Viral Hepat. 2018 Sep 10. doi: 10.1111/jvh.13001.
PubMed Abstract available

RODGERS MA, Holzmayer V, Vallari A, Olivo A, et al
Hepatitis C virus surveillance and identification of human pegivirus 2 in a large Cameroonian cohort.
J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12996.
PubMed Abstract available

DUONG MC, McLaws ML
Screening hemodialysis patients for hepatitis C in Vietnam: the inconsistency between common hepatitis C virus serological and virological tests.
J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12994.
PubMed Abstract available

VAN CAMPENHOUT MJH, Brouwer WP, Xie Q, Guo S, et al
Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg positive chronic hepatitis B infection: ARES long-term follow-up.
J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12997.
PubMed Abstract available

SUKRITI S, Choudhary MC, Maras JS, Sharma S, et al
Extracellular Vesicles From Hepatitis B Patients Serve As Reservoir Of Hepatitis B Virus DNA.
J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12995.
PubMed Abstract available

VROLING H, Oordt-Speets AM, Madeddu G, Babudieri S, et al
A systematic review on models of care effectiveness and barriers to Hepatitis C treatment in prison settings in the EU/EEA.
J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12998.
PubMed Abstract available

CHAN HLY, Chan FWS, Hui AJ, Li MKK, et al
Switching to Peginterferon for Chronic Hepatitis B Patients with Hepatitis B e Antigen Seroconversion on Entecavir - A Prospective Study.
J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.13000.
PubMed Abstract available

HONER ZU SIEDERDISSEN C, Maasoumy B, Cornberg M
New viral biomarkers for Hepatitis B: Are we able to change practice?
J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12993.
PubMed Abstract available

LAMPERTICO P, Brunetto MR, Craxi A, Gaeta GB, et al
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D.
J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12999.
PubMed Abstract available

SHEN J, Liu J, Li C, Wen T, et al
The prognostic significance of serum HBeAg on the recurrence and long-term survival after hepatectomy for hepatocellular carcinoma: A propensity score matching analysis.
J Viral Hepat. 2018;25:1057-1065.
PubMed Abstract available

WANG J, Yu Y, Li G, Shen C, et al
Natural history of serum HBV-RNA in chronic HBV infection.
J Viral Hepat. 2018;25:1038-1047.
PubMed Abstract available

August 2018

LAFFERTY L, Rance J, Grebely J, Lloyd AR, et al
Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison.
J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12987.
PubMed Abstract available

PERPINAN E, Caro-Perez N, Garcia-Gonzalez N, Gregori J, et al
Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals.
J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12986.
PubMed Abstract available

SAEED S, Moodie EE, Strumpf E, Gill J, et al
Real-World Impact of Direct Acting Antiviral Therapy on Health-Related Quality of Life in HIV/Hepatitis C Co-Infected Individuals.
J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12985.
PubMed Abstract available

JONES H, Patel P, Sears D
Electronic Reminders Increase Hepatitis C Screening, referral, treatment and cure.
J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12988.
PubMed Abstract available

MACIAS J, Granados R, Tellez F, Merino D, et al
Similar recovery of liver function after response to all oral HCV therapy in patients with cirrhosis with and without HIV coinfection.
J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12990.
PubMed Abstract available

LIM SG, Phyo WW, Shah SR, Win KM, et al
Findings from a large asian chronic hepatitis c real life study.
J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12989.
PubMed Abstract available

GROC S, Abbate JL, Le Gal F, Gerber A, et al
High Prevalence and Diversity of Hepatitis B and Hepatitis Delta Virus in Gabon.
J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12991.
PubMed Abstract available

DIRKS M, Haag K, Pflugrad H, Tryc AB, et al
Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients.
J Viral Hepat. 2018 Aug 18. doi: 10.1111/jvh.12979.
PubMed Abstract available

SINGH A, Kumari S, Kumar P, De A, et al
Sofosbuvir with NS5A Inhibitors in Hepatitis C Virus (HCV) Infection with Severe Renal Insufficiency.
J Viral Hepat. 2018 Aug 16. doi: 10.1111/jvh.12983.
PubMed Abstract available

ARYA RP, Mishra N, Biswas K, Arankalle VA, et al
Association of Toll-like receptor 4 polymorphism with Hepatitis E virus infected Indian patients.
J Viral Hepat. 2018 Aug 16. doi: 10.1111/jvh.12980.
PubMed Abstract available

MASETTI C, Lionetti R, Lupo M, Siciliano M, et al
Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hcv-related cirrhosis.
J Viral Hepat. 2018 Aug 16. doi: 10.1111/jvh.12982.
PubMed Abstract available

WANG S, Wang J, Fan MJ, Li TY, et al
Identified OAS3 gene variants associated with coexistence of HBsAg and anti-HBs in chronic HBV infection.
J Viral Hepat. 2018;25:904-910.
PubMed Abstract available

CHOI YH, Zhang X, Tran C, Skinner B, et al
Expression profiles of host immune response-related genes against HEV genotype 3 and genotype 1 infections in rhesus macaques.
J Viral Hepat. 2018;25:986-995.
PubMed Abstract available

WANG B, Carey I, Bruce M, Montague S, et al
HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues.
J Viral Hepat. 2018;25:886-893.
PubMed Abstract available

July 2018

SCOTT N, Sacks-Davis R, Pedrana A, Doyle J, et al
Eliminating hepatitis C: the importance of frequent testing of people who inject drugs in high prevalence settings.
J Viral Hepat. 2018 Jul 26. doi: 10.1111/jvh.12975.
PubMed Abstract available

PINTILIE H, Brook G
Commentary: A review of risk of hepatitis B and C transmission through biting or spitting.
J Viral Hepat. 2018 Jul 26. doi: 10.1111/jvh.12976.
PubMed Abstract available

DARVISHIAN M, Janjua NZ, Chong M, Cook D, et al
Estimating the impact of early hepatitis C virus clearance on hepatocellular carcinoma risk.
J Viral Hepat. 2018 Jul 26. doi: 10.1111/jvh.12977.
PubMed Abstract available

BILOUNGA NDONGO C, Eteki L, Siedner M, Mbaye R, et al
Prevalence and vaccination coverage of Hepatitis B among healthcare workers in Cameroon: A national seroprevalence survey.
J Viral Hepat. 2018 Jul 26. doi: 10.1111/jvh.12974.
PubMed Abstract available

SUGIURA A, Joshita S, Umemura T, Yamazaki T, et al
Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals.
J Viral Hepat. 2018 Jul 25. doi: 10.1111/jvh.12973.
PubMed Abstract available

WEI L, Chen D, Zhang B, Zhao Y, et al
Long-term Outcome and Recurrence of Hepatitis B Virus following Liver Transplantation from Hepatitis B Surface Antigen-positive Donors in a Chinese Population.
J Viral Hepat. 2018 Jul 15. doi: 10.1111/jvh.12972.
PubMed Abstract available

KIM BG, Park NH, Lee SB, Lee H, et al
Mortality, liver transplantation, and hepatic complications in patients with treatment-naive chronic hepatitis B treated with entecavir vs tenofovir.
J Viral Hepat. 2018 Jul 11. doi: 10.1111/jvh.12971.
PubMed Abstract available

NOMURA M, Tsuge M, Uchida T, Hiraga N, et al
CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients.
J Viral Hepat. 2018 Jul 11. doi: 10.1111/jvh.12970.
PubMed Abstract available

KABERG M, Naver G, Hammarberg A, Weiland O, et al
Incidence and spontaneous clearance of hepatitis C (HCV) in PWID at the Stockholm Needle Exchange - importance for HCV elimination.
J Viral Hepat. 2018 Jul 11. doi: 10.1111/jvh.12969.
PubMed Abstract available

HAYASHI K, Ishigami M, Ishizu Y, Kuzuya T, et al
Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy.
J Viral Hepat. 2018 Jul 11. doi: 10.1111/jvh.12967.
PubMed Abstract available

YUE X, Yang T, Zhao Y
Response to letter to the editor: Is revaccination required in children who received a full primary vaccination against hepatitis B in infancy?!
J Viral Hepat. 2018 Jul 11. doi: 10.1111/jvh.12968.
PubMed Abstract available

YOUNOSSI ZM, Stepanova M, Henry L, Han KH, et al
Sofosbuvir and Ledipasvir is Associated with High Sustained Virologic Response and Improvement of Health-Related Quality of Life in East Asian Patients with Hepatitis C Virus Infection.
J Viral Hepat. 2018 Jul 4. doi: 10.1111/jvh.12965.
PubMed Abstract available

MOHAMED Z, Rwegasha J, Kim JU, Shimakawa Y, et al
The hepatitis C cascade of care in people who inject drugs in Dar es Salaam, Tanzania.
J Viral Hepat. 2018 Jul 3. doi: 10.1111/jvh.12966.
PubMed Abstract available

LIU Y, Song C, Ni H, Jiao W, et al
UBE2L3, a susceptibility gene that plays oncogenic role in hepatitis B related hepatocellular carcinoma.
J Viral Hepat. 2018 Jul 3. doi: 10.1111/jvh.12963.
PubMed Abstract available

ANWAR N, Sherman KE
Transplanting organs from hepatitis B positive donors: Is it safe? Is it ethical?
J Viral Hepat. 2018 Jul 3. doi: 10.1111/jvh.12962.
PubMed Abstract available

TAN J, Mao X, Zhang G, Wang W, et al
Hepatitis B surface antigen positivity during pregnancy and risk of gestational diabetes mellitus: A systematic review and meta-analysis.
J Viral Hepat. 2018 Jul 3. doi: 10.1111/jvh.12964.
PubMed Abstract available

June 2018

HSIEH YH, Patel AV, Loevinsohn GS, Thomas DL, et al
Emergency Departments at the Crossroads of Intersecting Epidemics (HIV, HCV, Injection Drug Use, and Opioid Overdose) - Estimating HCV Incidence in an Urban Emergency Department Population.
J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12948.
PubMed Abstract available

KUMAR R
Hepatitis B Virus Infection and Diabetes Mellitus: An Adverse Relationship.
J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12949.
PubMed Abstract available

ZHOU TC, Li X, Chen LJ, Fan JH, et al
Differential expression profile of hepatic circular RNAs in chronic hepatitis B.
J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12944.
PubMed Abstract available

LUTTERKORT GL, Wranke A, Hengst J, Yurdaydin C, et al
Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy.
J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12947.
PubMed Abstract available

HARIDY J, Wigg A, Muller K, Ramachandran J, et al
Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience.
J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12943.
PubMed Abstract available

DINESHA TR, Boobalan J, Sivamalar S, Subashini D, et al
Occult HBV infection in HIV-infected adults and evaluation of pooled NAT for HBV.
J Viral Hepat. 2018;25:718-723.
PubMed Abstract available

May 2018

LIU Z, Yang Q, Shi O, Ye W, et al
The epidemiology of hepatitis B and hepatitis C infections in China from 2004 to 2014: an observational population based study.
J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12938.
PubMed Abstract available

KRAMER JR, Puenpatom A, Erickson K, Cao Y, et al
Real-World Effectiveness of Elbasvir/Grazoprevir in HCV-Infected Patients in the US Veterans Affairs Healthcare System.
J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12937.
PubMed Abstract available

AISYAH DN, Shallcross L, Hayward A, Aldridge RW, et al
Hepatitis C among Vulnerable Populations: A Seroprevalence Study of Homeless, People Who Inject Drugs and Prisoners in London.
J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12936.
PubMed Abstract available

MARCO A, Roget M, Cervantes M, Forne M, et al
Comparison of effectiveness and discontinuation of interferon-free therapy for hepatitis C in prison inmates and non-inmates.
J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12940.
PubMed Abstract available

ZHOU Y, Zhou YH
Is revaccination required in children who received a full primary vaccination against hepatitis B in infancy?
J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12941.
PubMed Abstract available

AGARWAL K, Ahn SH, Elkhashab M, Lau AH, et al
Safety and Efficacy of Vesatolimod (GS-9620) in Patients with Chronic Hepatitis B Who Are Not Currently on Antiviral Treatment.
J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12942.
PubMed Abstract available

JACKSON C, Gunson RN, Bradley-Stewart A, Bennet S, et al
Epidemiology and patient characteristics of hepatitis D virus infection in the West of Scotland 2011-2016.
J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12939.
PubMed Abstract available

FUJITA M, Sugiyama M, Sato Y, Nagashima K, et al
Hepatitis B virus reactivation in patients with rheumatoid arthritis: Analysis of the National Database of Japan.
J Viral Hepat. 2018 May 16. doi: 10.1111/jvh.12933.
PubMed Abstract available

JEONG Y, Jin B, Lee HW, Park HJ, et al
Evolution and Persistence of the Resistance-Associated Substitutions of Hepatitis C Virus after Direct-Acting Antiviral Treatment Failures.
J Viral Hepat. 2018 May 16. doi: 10.1111/jvh.12932.
PubMed Abstract available

AKRAM A, Islam SMR, Munshi SU, Tabassum S, et al
Detection of Hepatitis B Virus DNA among Chronic and potential Occult HBV patients in resource-limited settings by Loop-Mediated Isothermal Amplification assay.
J Viral Hepat. 2018 May 16. doi: 10.1111/jvh.12931.
PubMed Abstract available

CARDOSO AC, Perez RM, de Figueiredo-Mendes C, Carvalho Leite N, et al
Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with Controlled Attenuation Parameter (CAP).
J Viral Hepat. 2018 May 16. doi: 10.1111/jvh.12930.
PubMed Abstract available

DEMING R, Ford MM, Moore MS, Lim S, et al
Evaluation of a hepatitis C clinical care coordination program's effect on treatment initiation and cure: A surveillance-based propensity score matching approach.
J Viral Hepat. 2018 May 14. doi: 10.1111/jvh.12929.
PubMed Abstract available

CHENG CY, Wu HH, Zou H, Lo YC, et al
Epidemiological characteristics and associated factors of acute hepatitis A outbreak among HIV-coinfected men who have sex with men in Taiwan, June 2015-December 2016.
J Viral Hepat. 2018 May 9. doi: 10.1111/jvh.12926.
PubMed Abstract available

CHO YY, Lee JH, Chang Y, Nam JY, et al
Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients.
J Viral Hepat. 2018 May 9. doi: 10.1111/jvh.12927.
PubMed Abstract available

ZHOU TC, Lai X, Feng MH, Tang Y, et al
Systematic review and meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis e antigen seroconversion.
J Viral Hepat. 2018 May 9. doi: 10.1111/jvh.12928.
PubMed Abstract available

WANG J, Xia J, Zhang R, Yan X, et al
A novel index using routinely clinical parameters for predicting significant liver inflammation in chronic hepatitis B.
J Viral Hepat. 2018 May 9. doi: 10.1111/jvh.12925.
PubMed Abstract available

April 2018

CHI H, Japhary A, de Man RA, de Knegt RJ, et al
Younger Age and Language Barriers are Associated with Non-adherence to Clinical Follow-up in Hepatitis B Treatment.
J Viral Hepat. 2018 Apr 21. doi: 10.1111/jvh.12920.
PubMed Abstract available

MARTINELLO M, Bhagani S, Gane E, Orkin C, et al
Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.
J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12917.
PubMed Abstract available

NFOR ON, Wu MF, Debnath T, Lee CT, et al
Hepatitis B virus infection in Taiwan: The role of NTCP rs2296651 variant in relation to sex.
J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12912.
PubMed Abstract available

BOYD A, Moh R, Maylin S, Chekaraou MA, et al
Precore G1896A mutation is associated with reduced rates of HBsAg-seroclearance in treated HIV-hepatitis B virus co-infected patients from Western Africa.
J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12914.
PubMed Abstract available

WADE AJ, McCormack A, Roder C, McDonald K, et al
Aiming for elimination: outcomes of a consultation pathway supporting regional general practitioners to prescribe direct acting antiviral therapy for hepatitis C.
J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12910.
PubMed Abstract available

COUSIEN A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, et al
Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs; the case of France.
J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12919.
PubMed Abstract available

CAREY I, Byrne R, Childs K, Horner M, et al
Serum NGAL can act as an early renal safety biomarker during long-term nucleos(t)ide analogue antiviral therapy in chronic hepatitis B.
J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12916.
PubMed Abstract available

GENCAY M, Seffner A, Pabinger S, Gautier J, et al
Detection of in vivo hepatitis B virus surface antigen mutations - a comparison of four routine screening assays.
J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12915.
PubMed Abstract available

ANGELIDAKIS G, Hwang JP, Dandachi D, Economides MP, et al
Universal screening for hepatitis C: a needed approach in patients with hematologic malignancies.
J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12913.
PubMed Abstract available

YOO SH, Kwon JH, Nam SW, Kim HY, et al
Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: comparison with pegylated interferon-based therapy in chronic hepatitis C patients.
J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12918.
PubMed Abstract available

KOC OM, Savelkoul PHM, van Loo IHM, Peeters A, et al
Safety and immunogenicity of HBAI20 Hepatitis B vaccine in healthy naive and non-responding adults.
J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12909.
PubMed Abstract available

KUANG XJ, Jia RR, Huo RR, Yu JJ, et al
Systematic review of risk factors of hepatocellular carcinoma after Hepatitis B Surface Antigen seroclearance.
J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12905.
PubMed Abstract available

SRIDHAR S
Use of S17 fragment containing hepatitis E virus infectious clones in cell culture experiments: the fine print does matter.
J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12902.
PubMed Abstract available

TANG X, Allain JP, Wang H, Rong X, et al
Incidence of HBV infection in young Chinese blood donors born after mandatory implementation of neonatal hepatitis B vaccination nationwide.
J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12901.
PubMed Abstract available

WISLOFF T, White R, Dalgard O, Amundsen EJ, et al
Feasibility of reaching world health organization targets for hepatitis C and the cost-effectiveness of alternative strategies.
J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12904.
PubMed Abstract available

SCHNELL G, Tripathi R, Beyer J, Reisch T, et al
Characterization of Demographics and NS5A Genetic Diversity for HCV Genotype 4-Infected Patients with or without Cirrhosis Treated with Ombitasvir/Paritaprevir/Ritonavir.
J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12906.
PubMed Abstract available

MOORE MS, Bocour A, Winters A
Dialysis Facility Screening and Testing Practices in the Era of Improved Hepatitis C Treatment.
J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12907.
PubMed Abstract available

PENG Z, Hong-Bo D, Guang-Dong T, Xiao-Ke L, et al
Serum hepatitis B surface antigen correlates with fibrosis and necroinflammation: a multicentre perspective in China.
J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12903.
PubMed Abstract available

YUE X, Ge C, Zhuge S, He H, et al
Changes and analysis of anti-HBs titres after primary immunization in 1- to 16-year-old Chinese children: A hospital-based study.
J Viral Hepat. 2018;25:373-380.
PubMed Abstract available

March 2018

GODOY P, Carmona G, Manzanares S, Jane M, et al
Trends and risk factors of hepatitis A in Catalonia after the introduction of a hepatitis A+B vaccination program.
J Viral Hepat. 2018 Mar 31. doi: 10.1111/jvh.12900.
PubMed Abstract available

RICCO G, Popa DC, Cavallone D, Iacob S, et al
Quantification of serum markers of hepatitis B (HBV) and Delta virus (HDV) infections in patients with chronic HDV infection.
J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12895.
PubMed Abstract available

HOSHINO K, Sugiyama M, Date T, Maruwaka S, et al
Phylogenetic and phylodynamic analysis of hepatitis C virus subtype 1a in Okinawa, Japan.
J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12898.
PubMed Abstract available

WANG H, Swann R, Thomas E, Innes HA, et al
Impact of previous hepatitis B infection on the clinical outcomes from chronic hepatitis C? A population-level analysis.
J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12897.
PubMed Abstract available

BOYD SD, Harrington P, Komatsu TE, Naeger LK, et al
HCV Genotype 4, 5, and 6: Distribution of Viral Subtypes and Sustained Virologic Response Rates in Clinical Trials of Approved Direct-acting Antiviral Regimens.
J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12896.
PubMed Abstract available

NJOUOM R, Siffert I, Texier G, Lachenal G, et al
The burden of Hepatitis C virus in Cameroon: Spatial epidemiology and historical perspective.
J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12894.
PubMed Abstract available

GOOSSENS N, de Vito C, Mangia A, Clement S, et al
Effect of Hepatitis B virus on Steatosis in Hepatitis C virus co-infected subjects: a multi-center study and systematic review.
J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12891.
PubMed Abstract available

LI M, Gan Y, Fan C, Yuan H, et al
Hepatitis B virus and risk of non-Hodgkin lymphoma: an updated meta-analysis of 58 studies.
J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12892.
PubMed Abstract available

FEDELI U
Increasing mortality associated with the more recent epidemic wave of Hepatitis C virus infection in Northern Italy.
J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12893.
PubMed Abstract available

PAPATHEODORIDIS GV, Hatzakis A, Cholongitas E, Baptista-Leite R, et al
Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.
J Viral Hepat. 2018;25 Suppl 1:6-17.
PubMed Abstract available

XIANG-CHUN D, Xiao-Qing Y, Ting-Ting Y, Zhen-Hui L, et al
Alpha-enolase regulates hepatitis B virus replication through suppression of the interferon signalling pathway.
J Viral Hepat. 2018;25:289-295.
PubMed Abstract available

February 2018

DUARTE G, Williams CJ, Vasconcelos P, Nogueira P, et al
Capacity to report on mortality attributable to chronic Hepatitis B and C infections by Member States: an exercise to monitor progress toward viral hepatitis elimination.
J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12882.
PubMed Abstract available

MACLEAN CD, Berger C, Cangiano ML, Ziegelman D, et al
Impact of Electronic Reminder Systems on Hepatitis C Screening in Primary Care.
J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12885.
PubMed Abstract available

CHEN JY, Ren Y, Yan P, Belina ME, et al
Tricyclic Antidepressant Use and the Risk of Fibrosis Progression in Hepatitis C-Infected Persons: Results from ERCHIVES.
J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12884.
PubMed Abstract available

LI J, Zhang T, Gordon SC, Rupp LB, et al
Impact of sustained virological response on risk of type 2 diabetes among hepatitis C patients in the US.
J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12887.
PubMed Abstract available

YOUNOSSI ZM, Tanaka A, Eguchi Y, Henry L, et al
Treatment of Hepatitis C Virus Leads to Economic Gains Related to Reduction in Cases of Hepatocellular Carcinoma and Decompensated Cirrhosis in Japan.
J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12886.
PubMed Abstract available

OLVEIRA A, Dominguez L, Troya J, Arias A, et al
Persistently altered liver test results in hepatitis C patients after sustained virological response with direct-acting antivirals.
J Viral Hepat. 2018 Feb 24. doi: 10.1111/jvh.12883.
PubMed Abstract available

CACOUB P, Buggisch P, Carrion JA, S Cooke G, et al
Direct Medical Costs Associated with the Extrahepatic Manifestations of Hepatitis C Infection in Europe.
J Viral Hepat. 2018 Feb 24. doi: 10.1111/jvh.12881.
PubMed Abstract available

LEE WC, Chou HS, Lee CS, Wu TH, et al
Viral activity and outcome of hepatitis B surface antigen-positive grafts in deceased liver transplantation.
J Viral Hepat. 2018 Feb 12. doi: 10.1111/jvh.12880.
PubMed Abstract available

CORTESI PA, Belli LS, Facchetti R, Mazzarelli C, et al
The optimal timing of Hepatitis C therapy in liver transplant eligible patients: cost-effectiveness analysis of new opportunities.
J Viral Hepat. 2018 Feb 6. doi: 10.1111/jvh.12877.
PubMed Abstract available

HEDENSTIERNA M, Nangarhari A, El-Sabini A, Weiland O, et al
Cirrhosis, high age and high body mass index are risk factors for persisting advanced fibrosis after sustained virologic response in chronic hepatitis C.
J Viral Hepat. 2018 Feb 6. doi: 10.1111/jvh.12879.
PubMed Abstract available

DELFINO CM, Cerrudo CS, Biglione M, Oubina JR, et al
A comprehensive bioinformatic analysis of hepatitis D virus (HDV) full-length genomes.
J Viral Hepat. 2018 Feb 6. doi: 10.1111/jvh.12876.
PubMed Abstract available

ZHONG GC, Wu YL, Hao FB, Rao XW, et al
Current but not past hepatitis B virus infection is associated with a decreased risk of nonalcoholic fatty liver disease in the Chinese population: A case-control study with propensity score analysis.
J Viral Hepat. 2018 Feb 6. doi: 10.1111/jvh.12878.
PubMed Abstract available

ZAKARIA HM, Salem TA, El-Araby HA, Salama RM, et al
Steroid therapy in children with fulminant hepatitis A.
J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12873.
PubMed Abstract available

PREDA CM, Popescu CP, Baicus C, Constantinescu I, et al
Risk of HBV reactivation in HBV+HCV coinfected patients with compensated liver cirrhosis treated with Ombitasvir, Paritaprevir/r+Dasabuvir+Ribavirin.
J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12872.
PubMed Abstract available

LUXENBURGER H, Grass F, Baermann J, Boettler T, et al
Differential virus-specific CD8(+) T-cell epitope repertoire in hepatitis C virus genotype 1 versus 4.
J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12874.
PubMed Abstract available

WALKER AJ, Peacock CJ, Pedergnana V, Irving WL, et al
Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: A systematic review.
J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12871.
PubMed Abstract available

January 2018

ALVAREZ-OSSORIO MJ, Sarmento E Castro R, Granados R, Macias J, et al
Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort.
J Viral Hepat. 2018 Jan 28. doi: 10.1111/jvh.12867.
PubMed Abstract available

GUPTA S, Rout G, Patel AH, Mahanta M, et al
Efficacy of Generic Oral Directly Acting Agents in Patients with Hepatitis C Virus Infection.
J Viral Hepat. 2018 Jan 28. doi: 10.1111/jvh.12870.
PubMed Abstract available

FABER M, Willrich N, Schemmerer M, Rauh C, et al
Hepatitis E virus seroprevalence, seroincidence and seroreversion in the German adult population.
J Viral Hepat. 2018 Jan 28. doi: 10.1111/jvh.12868.
PubMed Abstract available

HARRIS M, Bonnington O, Harrison G, Hickman M, et al
Understanding hepatitis C intervention success: Qualitative findings from the HepCATT study.
J Viral Hepat. 2018 Jan 25. doi: 10.1111/jvh.12869.
PubMed Abstract available

YANG C, Yu W, Bi Y, Long F, et al
Increased estradiol in hepatitis E virus infected pregnant women promote viral replication.
J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12865.
PubMed Abstract available

ZHOU PP, Xu J, Dai MJ, Shi YY, et al
The immunosuppressive effects of CD4(+) CD25(+) regulatory T cells on dendritic cells in patients with chronic hepatitis B.
J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12863.
PubMed Abstract available

AYOUB HH, Al Kanaani Z, Abu-Raddad LJ
Characterizing the temporal evolution of the hepatitis C virus epidemic in Pakistan.
J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12864.
PubMed Abstract available

AISYAH DN, Shallcross L, Hully AJ, O'Brien A, et al
Assessing Hepatitis C Spontaneous Clearance and Understanding Associated Factors: A Systematic Review and Meta-Analysis.
J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12866.
PubMed Abstract available

COLOMBO M, Boccaccio V
Hepatitis C eradication with DAA and risk of liver cancer recurrence: the debate unrests.
J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12862.
PubMed Abstract available

CHO H, Ahn H, Lee DH, Lee JH, et al
Entecavir and Tenofovir Reduce Hepatitis B Virus-related Hepatocellular Carcinoma Recurrence More Effectively than Other Antivirals.
J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12855.
PubMed Abstract available

LAU KC, Osiowy C, Giles E, Lusina B, et al
Deep Sequencing Shows Low Level Oncogenic Hepatitis B Virus Variants Persisting Post-Liver Transplant Despite Potent Anti-HBV Prophylaxis.
J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12860.
PubMed Abstract available

FLISIAK R, Zarebska-Michaluk D, Janczewska E, Staniaszek A, et al
Treatment of HCV infection in Poland at the beginning of the interferon-free era - the EpiTer-2 study.
J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12861.
PubMed Abstract available

YOUNG K, Haq K, MacLean S, Dudani R, et al
Development of a recombinant murine tumor model using hepatoma cells expressing hepatitis C virus (HCV) non-structural antigens.
J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12856.
PubMed Abstract available

FALADE-NWULIA O, Sulkowski MS, Merkow A, Latkin C, et al
Understanding and addressing hepatitis C reinfection in the oral direct acting antiviral era.
J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12859.
PubMed Abstract available

SCHUTZ A, Moser S, Schwanke C, Schubert R, et al
Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk for non-adherence to direct-acting antivirals.
J Viral Hepat. 2018 Jan 5. doi: 10.1111/jvh.12857.
PubMed Abstract available

December 2017

EL KASSAS M, Funk AL, Salaheldin M, Shimakawa Y, et al
Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C infected Egyptian cohort: a comparative analysis.
J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12854.
PubMed Abstract available

SULKOWSKI MS, Feld JJ, Lawitz E, Felizarta F, et al
Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12853.
PubMed Abstract available

HAJARIZADEH B, Grebely J, Matthews GV, Martinello M, et al
Uptake of direct acting antiviral treatment for chronic hepatitis C in Australia.
J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12852.
PubMed Abstract available

CHEN CH, Hsu YC, Lu SN, Hung CH, et al
The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients.
J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12851.
PubMed Abstract available

KOZUKA R, Hai H, Motoyama H, Hagihara A, et al
The Presence of Multiple NS5A RASs is Associated with the Outcome of Sofosbuvir and Ledipasvir Therapy in NS5A Inhibitor-Naive Patients with Chronic HCV Genotype 1b Infection in a Real-World Cohort.
J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12850.
PubMed Abstract available

MCNAUGHTON AL, Sreenu VB, Wilkie G, Gunson R, et al
Prevalence of mixed genotype hepatitis C virus infections in the UK as determined by genotype-specific PCR and deep sequencing.
J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12849.
PubMed Abstract available

GUBAY F, Staunton R, Metzig C, Abubakar I, et al
Assessing uncertainty in the burden of Hepatitis C Virus: comparison of estimated disease burden and treatment costs in the UK.
J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12847.
PubMed Abstract available

ZENG QL, Xu GH, Wang B, Li ZQ, et al
Prophylactic antiviral therapy for the prevention of mother-to-child transmission of hepatitis B virus can be stopped at delivery.
J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12848.
PubMed Abstract available

SIMMONS R, Ireland G, Irving W, Hickman M, et al
Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals.
J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12844.
PubMed Abstract available

RODRIGUEZ DE SANTIAGO E, Velazquez Kennedy K, Garcia Gonzalez M, Gea Rodriguez F, et al
HCV-positive lymphoma after sustained virological response with direct-acting antiviral agents: The game is not over after HCV eradication.
J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12843.
PubMed Abstract available

READ SA, Parnell G, Booth D, Douglas MW, et al
The Antiviral Role of Zinc and Metallothioneins in Hepatitis C Infection.
J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12845.
PubMed Abstract available

ERMAN A, Sathya A, Nam A, Bielecki JM, et al
Estimating Chronic Hepatitis C Prognosis Using Transient Elastography-Based Liver Stiffness: A Systematic Review and Meta-Analysis.
J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12846.
PubMed Abstract available

LIU DP, Lu W, Zhang ZQ, Wang YB, et al
Comparative evaluation of GPR versus APRI and FIB-4 in predicting different levels of liver fibrosis of chronic hepatitis B.
J Viral Hepat. 2017 Dec 12. doi: 10.1111/jvh.12842.
PubMed Abstract available

FERREIRA GLC, Marano C, De Moerlooze L, Guignard A, et al
Incidence and prevalence of hepatitis B in patients with diabetes mellitus in the UK: a population-based cohort study using the UK Clinical Practice Research Datalink.
J Viral Hepat. 2017 Dec 8. doi: 10.1111/jvh.12841.
PubMed Abstract available

NAM JY, Chang Y, Cho H, Kang SH, et al
Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.
J Viral Hepat. 2017 Dec 1. doi: 10.1111/jvh.12838.
PubMed Abstract available

November 2017

CHEN Y, Xie C, Zhang Y, Li Y, et al
Knowledge regarding Hepatitis B Mother-to-child Transmission among Healthcare Workers in South China.
J Viral Hepat. 2017 Nov 30. doi: 10.1111/jvh.12839.
PubMed Abstract available

ALAVI M, Janjua NZ, Chong M, Grebely J, et al
Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: an international comparison.
J Viral Hepat. 2017 Nov 30. doi: 10.1111/jvh.12837.
PubMed Abstract available

TAMORI A, Abiru S, Enomoto H, Kioka K, et al
Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy.
J Viral Hepat. 2017 Nov 30. doi: 10.1111/jvh.12840.
PubMed Abstract available

CARLTON-SMITH C, Holmes JA, Naggie S, Lidofsky A, et al
IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR.
J Viral Hepat. 2017 Nov 29. doi: 10.1111/jvh.12836.
PubMed Abstract available

WANG Y, Liang X, Yang J, Wang H, et al
Improved performance of quantitative collagen parameters versus standard histology in longitudinal assessment of non-advanced liver fibrosis for chronic hepatitis B.
J Viral Hepat. 2017 Nov 29. doi: 10.1111/jvh.12835.
PubMed Abstract available

LIU J, Zhang S, Liu M, Wang Q, et al
Distribution of ABO/Rh blood groups and their association with hepatitis B virus infection in 3.8 million Chinese adults: a population-based cross-sectional study.
J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12829.
PubMed Abstract available

LEE HR, Cho YY, Lee GY, You DG, et al
A direct role for hepatitis B virus X protein in inducing mitochondrial membrane permeabilization.
J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12831.
PubMed Abstract available

YOUNOSSI ZM, Stepanova M, Schwarz KB, Wirth S, et al
Quality of Life in Adolescents with Hepatitis C Treated with Sofosbuvir and Ribavirin.
J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12830.
PubMed Abstract available

JENG WJ, Chen YC, Liaw YF
Great and rapid HBsAg decline in patients with on-treatment hepatitis flare in early phase of potent antiviral therapy.
J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12833.
PubMed Abstract available

TANAKA J, Akita T, Ohisa M, Sakamune K, et al
Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011.
J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12828.
PubMed Abstract available

HU Y, Xu C, Xu B, Hu L, et al
Safety and efficacy of telbivudine in late pregnancy to prevent mother-to-child transmission of hepatitis B virus: a multicenter prospective cohort study.
J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12834.
PubMed Abstract available

HSU YC, Ho HJ, Lee TY, Huang YT, et al
Temporal Trend and Risk Determinants of Hepatocellular Carcinoma in Chronic Hepatitis B Patients on Entecavir or Tenofovir.
J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12832.
PubMed Abstract available

KEISER O, Giudici F, Mullhaupt B, Junker C, et al
Trends in hepatitis C-related mortality in Switzerland.
J Viral Hepat. 2017 Nov 20. doi: 10.1111/jvh.12803.
PubMed Abstract available

BROWN A, Hezode C, Zuckerman E, Foster GR, et al
Efficacy and safety of 12 weeks of elbasvir +/- grazoprevir +/- ribavirin in participants with HCV genotype 2, 4, 5, or 6 infection: the C-SCAPE study.
J Viral Hepat. 2017 Nov 20. doi: 10.1111/jvh.12801.
PubMed Abstract available

DUCHESNE L, Lacombe K
Innovative technologies for point-of-care testing of viral hepatitis in low-resource and decentralized settings.
J Viral Hepat. 2017 Nov 13. doi: 10.1111/jvh.12827.
PubMed Abstract available

BHARDWAJ N, Ragonnet-Cronin M, Murrell B, Chodavarapu K, et al
Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens.
J Viral Hepat. 2017 Nov 7. doi: 10.1111/jvh.12825.
PubMed Abstract available

SALMON-CERON D, Mondelli MU, Maticic M, Arends JE, et al
The success of HCV cure: every rose has its thorn.
J Viral Hepat. 2017 Nov 7. doi: 10.1111/jvh.12823.
PubMed Abstract available

HIKITA H, Sato M, Sato M, Soroida Y, et al
Disappearance of Perihepatic Lymph Node Enlargement after hepatitis C viral eradication with direct acting antivirals.
J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12819.
PubMed Abstract available

CANNIZZO ES, Tincati C, Binda F, Ronzi P, et al
Unconventional T-cells in Chronic Hepatitis B Patients on Long-Term Suppressive Therapy with Tenofovir followed by a Peg-IFN Add-On Strategy: a randomized study.
J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12820.
PubMed Abstract available

DE ARAUJO NETO JM, Coelho HSM, Chindamo MC, da Motta Rezende GF, et al
Lower levels of dehydroepiandrosterone sulfate are associated with more advanced liver fibrosis in chronic hepatitis C.
J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12812.
PubMed Abstract available

MENDES LC, Ferreira PA, Miotto N, Zanaga L, et al
Elastogram quality assessment score in Vibration Controlled Transient Elastography: Diagnostic performance compared to digital morphometric analysis of liver biopsy in chronic hepatitis C.
J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12822.
PubMed Abstract available

FOSTER G
Editorial for "Supplement on Optimal Therapy for Chronic Hepatitis B in China".
J Viral Hepat. 2017;24 Suppl 1:3.
PubMed

LIU J, Chen T, Zhao Y
Telbivudine therapy for gravidas with chronic hepatitis B infection and patients at risk of renal impairment.
J Viral Hepat. 2017;24 Suppl 1:6-11.
PubMed Abstract available

PAN HY, Pan HY, Song WY, Zheng W, et al
Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.
J Viral Hepat. 2017;24 Suppl 1:29-35.
PubMed Abstract available

LUO XD, Chen XF, Zhou Y, Chen XP, et al
Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNalpha-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
J Viral Hepat. 2017;24 Suppl 1:36-42.
PubMed Abstract available

YI W, Li MH, Xie Y, Wu J, et al
Prospective cohort study on the efficacy and safety of telbivudine used throughout pregnancy in blocking mother-to-child transmission of hepatitis B virus.
J Viral Hepat. 2017;24 Suppl 1:49-56.
PubMed Abstract available

LI SY, Li H, Xiong YL, Liu F, et al
Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study.
J Viral Hepat. 2017;24 Suppl 1:12-20.
PubMed Abstract available

HUANG D, Sansas B, Jiang JH, Gong QM, et al
Recognition of Core- and Polymerase-derived immunogenic peptides included in novel therapeutic vaccine by T cells from Chinese chronic hepatitis B patients.
J Viral Hepat. 2017;24 Suppl 1:66-74.
PubMed Abstract available

SHANG J, Wen Q, Wang CC, Liu K, et al
Safety and efficacy of telbivudine for chronic hepatitis B during the entire pregnancy: Long-term follow-up.
J Viral Hepat. 2017;24 Suppl 1:43-48.
PubMed Abstract available

WANG ML, Chen EQ, Zhang DM, Du LY, et al
Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy.
J Viral Hepat. 2017;24 Suppl 1:21-28.
PubMed Abstract available

REN H
The experience of management of chronic hepatitis B in China.
J Viral Hepat. 2017;24 Suppl 1:4-5.
PubMed Abstract available

October 2017

CAMPANA B, Calabrese D, Matter MS, Terracciano LM, et al
In vivo analysis at the cellular level reveals similar steatosis induction in both HCV genotype 1 and 3 infections.
J Viral Hepat. 2017 Oct 31. doi: 10.1111/jvh.12816.
PubMed Abstract available

LIANG X, Xie Q, Tan D, Ning Q, et al
Interpretation of liver stiffness measurement based approach for the monitoring of hepatitis B patients with antiviral therapy: a 2-year prospective study.
J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12814.
PubMed Abstract available

MA N, Zhang X, Yang L, Zhou J, et al
Role of Functional IFNL4, IFNLR1, IFNA, IFNAR2 Polymorphisms in Hepatitis B virus-related liver disease in Han Chinese population.
J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12817.
PubMed Abstract available

CHOI HY, Kim Y, Cho H, Kim BH, et al
Risk of diabetes in viral hepatitis B or C patients compared to that in non-infected individuals in Korea, 2002-2013: A population-based cohort study.
J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12815.
PubMed Abstract available

MARCELLIN F, Morlat P, Wittkop L, Salmon-Ceron D, et al
Impaired patient-reported outcomes persist in HIV-HCV co-infected patients and in cirrhotic patients despite HCV clearance.
J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12811.
PubMed Abstract available

OW MM, Hegazy D, Warshow UM, Cramp ME, et al
Enhanced natural killer cell activity is found in exposed uninfected recipients of hepatitis C-contaminated blood.
J Viral Hepat. 2017 Oct 24. doi: 10.1111/jvh.12810.
PubMed Abstract available

SALUDES V, Folch C, Morales-Carmona A, Ferrer L, et al
Community-based screening of hepatitis C with a one-step RNA detection algorithm from dried-blood spots: analysis of key populations in Barcelona, Spain.
J Viral Hepat. 2017 Oct 20. doi: 10.1111/jvh.12809.
PubMed Abstract available

YOUNOSSI ZM, Chan HLY, Dan YY, Lee MH, et al
Impact of Ledipasvir/Sofosbuvir on the Work Productivity of Genotype 1 Chronic Hepatitis C Patients in Asia.
J Viral Hepat. 2017 Oct 20. doi: 10.1111/jvh.12808.
PubMed Abstract available

NAYLOR PH, Mutchnick MG
Immunotherapy for Hepatitis B in the Direct Acting Anti-viral Era: Reevaluating the Thymosin alpha1 Efficacy Trials in Light of a Combination Therapy Approach.
J Viral Hepat. 2017 Oct 20. doi: 10.1111/jvh.12807.
PubMed Abstract available

WEN X, Su H, Wang Y, Pu Z, et al
Prevalence and natural course of occult hepatitis B virus infection in residents of two communities of Wuwei City, Gansu Province, China.
J Viral Hepat. 2017 Oct 15. doi: 10.1111/jvh.12805.
PubMed Abstract available

WONG NS, Lee CK, Ng SC, Wong HK, et al
Prevalence of hepatitis C infection and its associated factors in healthy adults without identifiable route of transmission.
J Viral Hepat. 2017 Oct 15. doi: 10.1111/jvh.12804.
PubMed Abstract available

MARRONE A, Capoluongo N, D'Amore C, Pisaturo M, et al
Eighteen-month-lamivudine-prophylaxis on preventing occult hepatitis b virus (hbv) infection reactivation in patients with hematologic malignancies receiving immunosuppression therapy.
J Viral Hepat. 2017 Oct 13. doi: 10.1111/jvh.12802.
PubMed Abstract available

CAMUS G, Han B, Asselah T, Hsieh D, et al
Resistance Characterization of Ledipasvir and Velpatasvir in Hepatitis C Virus Genotype 4.
J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12795.
PubMed Abstract available

TANG L, Parker A, Flores Y, Dellario M, et al
Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: highly effective in a predominantly black male patient population.
J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12796.
PubMed Abstract available

NORDMANN S, Vilotitch A, Roux P, Esterle L, et al
Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus co-infected patients (ANRS CO13-HEPAVIH).
J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12797.
PubMed Abstract available

SRIDHAR S, Chan JFW, Yap DYH, Teng JLL, et al
Genotype 4 hepatitis E virus is a cause of chronic hepatitis in renal transplant recipients in Hong Kong.
J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12799.
PubMed Abstract available

WEIL C, Mehta D, Koren G, Pinsky B, et al
Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider.
J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12800.
PubMed Abstract available

CHEN DS, Hamoudi W, Mustapha B, Layden J, et al
Strategies to manage hepatitis C virus infection disease burden-Volume 4.
J Viral Hepat. 2017;24 Suppl 2:44-63.
PubMed Abstract available

MAAROUFI A, Vince A, Himatt SM, Mohamed R, et al
Historical epidemiology of hepatitis C virus in select countries-volume 4.
J Viral Hepat. 2017;24 Suppl 2:8-24.
PubMed Abstract available

DORE GJ, Hatzakis A, Negro F, Waked I, et al
Estimating HCV disease burden-volume 4 (editorial).
J Viral Hepat. 2017;24 Suppl 2:4-7.
PubMed Abstract available

CHAN HLY, Chen CJ, Omede O, Al Qamish J, et al
The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4.
J Viral Hepat. 2017;24 Suppl 2:25-43.
PubMed Abstract available

August 2017

SERPER M, Forde KA, Kaplan DE
Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: data from a national US cohort.
J Viral Hepat. 2017 Aug 28. doi: 10.1111/jvh.12784.
PubMed Abstract available

ZHENG H, Cui FQ, Wang FZ, Huang LF, et al
The epidemiology of hepatitis B virus infection in women of reproductive age in highly endemic areas in China.
J Viral Hepat. 2017 Aug 23. doi: 10.1111/jvh.12757.
PubMed Abstract available

SHAFRAN SD, Shaw D, Charafeddine M, Agarwal K, et al
Efficacy and Safety Results of Patients with HCV Genotype 2 or 3 Infection Treated with Ombitasvir/Paritaprevir/ritonavir and Sofosbuvir with or without Ribavirin (QUARTZ II-III).
J Viral Hepat. 2017 Aug 20. doi: 10.1111/jvh.12782.
PubMed Abstract available

KITRINOS KM, Corsa AC, Worth A, Hedskog C, et al
Nonstructural Protein 5A (NS5A) Resistance Profile in Patients with Chronic Hepatitis C Treated with Ledipasvir-Containing Regimens Without Sofosbuvir.
J Viral Hepat. 2017 Aug 20. doi: 10.1111/jvh.12783.
PubMed Abstract available

KRAMER JR, El-Serag HB, Taylor TJ, White DL, et al
Hepatitis C virus-related complications are increasing in women veterans: A national cohort study.
J Viral Hepat. 2017 Aug 16. doi: 10.1111/jvh.12728.
PubMed Abstract available

BARONE M, Iannone A, Shahini E, Ippolito AM, et al
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: the ITAL-C network study.
J Viral Hepat. 2017 Aug 8. doi: 10.1111/jvh.12765.
PubMed Abstract available

MERCHANTE N, Aldamiz-Echevarria T, Garcia-Alvarez M, Rivero-Juarez A, et al
Bacterial translocation and clinical progression of HCV-related cirrhosis in HIV-infected patients.
J Viral Hepat. 2017 Aug 7. doi: 10.1111/jvh.12769.
PubMed Abstract available

VON FELDEN J, Scheurich C, Yamamura J, Brainard DM, et al
Successful treatment of chronic hepatitis C with ground ledipasvir / sofosbuvir in a patient with Crohn's disease and short bowel syndrome.
J Viral Hepat. 2017 Aug 7. doi: 10.1111/jvh.12768.
PubMed Abstract available

FOURNIER C, Hoffmann TW, Morel V, Descamps V, et al
Claudin-1, miR-122 and Apolipoprotein E transduction improves the permissivity of SNU-182, SNU-398 and SNU-449 Hepatoma cells to Hepatitis C Virus.
J Viral Hepat. 2017 Aug 3. doi: 10.1111/jvh.12767.
PubMed Abstract available

HUI RW, Seto WK, Cheung KS, Mak LY, et al
Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case control study.
J Viral Hepat. 2017 Aug 3. doi: 10.1111/jvh.12766.
PubMed Abstract available

July 2017

HALLAGER S, Ladelund S, Kjaer MS, Madsen LG, et al
Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: a nationwide cohort study.
J Viral Hepat. 2017 Jul 27. doi: 10.1111/jvh.12764.
PubMed Abstract available

JACKA B, Bray B, Applegate TL, Marshall BD, et al
Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach.
J Viral Hepat. 2017 Jul 18. doi: 10.1111/jvh.12758.
PubMed Abstract available

SOLOMON SS, Sulkowski MS, Amrose P, Srikrishnan AK, et al
Directly Observed Therapy of Sofosbuvir/Ribavirin +/- Peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT).
J Viral Hepat. 2017 Jul 18. doi: 10.1111/jvh.12761.
PubMed Abstract available

CHAKRABARTY G, Bruce M, Horner M, Wang B, et al
Can Quantitative Hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients?
J Viral Hepat. 2017 Jul 14. doi: 10.1111/jvh.12756.
PubMed Abstract available

CALVARUSO V, Ferraro D, Licata A, Bavetta MG, et al
HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct acting antivirals.
J Viral Hepat. 2017 Jul 13. doi: 10.1111/jvh.12754.
PubMed Abstract available

GARDNER SD, Kim J, Baptiste-Brown S, Lopez V, et al
GSK2878175, a pan-genotypic non-nucleoside NS5B polymerase inhibitor, in healthy and treatment-naive chronic hepatitis C subjects.
J Viral Hepat. 2017 Jul 10. doi: 10.1111/jvh.12753.
PubMed Abstract available

AL-QAHTANI AA, Al-Anazi MR, Nazir N, Wani K, et al
Association of Single Nucleotide Polymorphisms in MicroRNAs with Susceptibility to Hepatitis B Virus Infection and HBV-related Liver Complications: A Study in a Saudi Arabian Population.
J Viral Hepat. 2017 Jul 7. doi: 10.1111/jvh.12749.
PubMed Abstract available

SALAZAR-VIZCAYA L, Kouyos RD, Fehr J, Braun D, et al
On the potential of a short-term intensive intervention to interrupt HCV transmission in HIV-positive men who have sex with men: a mathematical modelling study.
J Viral Hepat. 2017 Jul 7. doi: 10.1111/jvh.12752.
PubMed Abstract available

LI Q, Lu C, Li W, Huang Y, et al
The gamma-glutamyl transpeptidase to albumin ratio predicts significant fibrosis and cirrhosis in chronic hepatitis B patients.
J Viral Hepat. 2017 Jul 7. doi: 10.1111/jvh.12751.
PubMed Abstract available

June 2017

BENOVA L, Awad SF, Abu-Raddad LJ
Estimate of vertical transmission of Hepatitis C virus in Pakistan in 2007 and 2012 birth cohorts.
J Viral Hepat. 2017 Jun 29. doi: 10.1111/jvh.12748.
PubMed Abstract available

LI Y, Li Y, Zhang L, Li W, et al
Hepatitis C virus infection and risk of multiple myeloma: evidence from a meta-analysis based on 17 case-control studies.
J Viral Hepat. 2017 Jun 28. doi: 10.1111/jvh.12742.
PubMed Abstract available

SIDDIQUI ZI, Farooqui SR, Azam SA, Afroz M, et al
A comparative study of hepatitis B virus X protein mutants K130M, V131I and KV130/131MI to investigate their roles in fibrosis, cirrhosis and hepatocellular carcinoma.
J Viral Hepat. 2017 Jun 27. doi: 10.1111/jvh.12747.
PubMed Abstract available

TENG W, Hsieh YC, Lui KW, Chen WT, et al
Eradication of hepatitis C virus profoundly prolongs survival in hepatocellular carcinoma patients receiving transarterial chemoembolization.
J Viral Hepat. 2017 Jun 22. doi: 10.1111/jvh.12745.
PubMed Abstract available

SCHIAVINATO A, Zanetto A, Pantano G, Tosato F, et al
Polyclonal and monoclonal B-lymphocytes response in HCV patients treated with direct-acting antiviral agents.
J Viral Hepat. 2017 Jun 22. doi: 10.1111/jvh.12746.
PubMed Abstract available

DE LA TORRE AN, Castaneda I, Ahmad M, Ekholy N, et al
Audio Computer Assisted Survey Interview and Patient Navigation to Increase Chronic Viral Hepatitis Diagnosis and Linkage to Care in Urban Health Clinics.
J Viral Hepat. 2017 Jun 21. doi: 10.1111/jvh.12744.
PubMed Abstract available

DIRKS M, Pflugrad H, Weissenborn K
Response to letter to the editor: Persistent neuropsychiatric impairment in HCV patients - or educational mismatch?!
J Viral Hepat. 2017 Jun 21. doi: 10.1111/jvh.12740.
PubMed Abstract available

YANG R, Gui X, Xiong Y, Gao S, et al
Long-term Follow-up of Patients Triply Infected with HIV and Hepatitis B and C Viruses in a Comprehensive Hospital in Central China.
J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12739.
PubMed Abstract available

GADE A
Persistent neuropsychiatric impairment in HCV patients - or educational mismatch?!
J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12743.
PubMed Abstract available

KAWAGISHI N, Suda G, Onozawa M, Kimura M, et al
Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.
J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12737.
PubMed Abstract available

STELMA F, van der Ree MH, Jansen L, Peters MW, et al
HBsAg loss after peginterferon and nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up.
J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12738.
PubMed Abstract available

JOHNSON K, Green PK, Ioannou GN
Implications of HCV RNA level at week 4 of direct antiviral treatments for Hepatitis C.
J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12731.
PubMed Abstract available

WONG RJ, Nguyen MT, Trinh HN, Chan C, et al
Hepatitis B Surface Antigen Loss and Sustained Viral Suppression in Asian Chronic Hepatitis B Patients: A Community-Based Real World Study.
J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12736.
PubMed Abstract available

KIM HS, Rotundo L, Yang JD, Kim D, et al
Racial/ethnic disparities in the prevalence and awareness of Hepatitis B virus infection and immunity in the United States.
J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12735.
PubMed Abstract available

EL SHERIF O, Afhdal N, Curry M
No one size fits all - shortening duration of therapy with direct acting antivirals for Hepatitis C genotype 1 infection.
J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12734.
PubMed Abstract available

NING L, Lin W, Hu X, Rong F, et al
Prevalence of chronic kidney disease in patients with chronic hepatitis B: A cross-sectional survey.
J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12733.
PubMed Abstract available

LOK AS, Ganova-Raeva L, Cloonan Y, Punkova L, et al
Prevalence of Hepatitis B Antiviral Drug Resistance Variants in North American Patients with Chronic Hepatitis B Not Receiving Antiviral Treatment.
J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12732.
PubMed Abstract available

SHARMA S, Kumar A, Kar P, Agarwal S, et al
Risk factors for vertical transmssion of hepatitis E virus infection.
J Viral Hepat. 2017 Jun 1. doi: 10.1111/jvh.12730.
PubMed Abstract available

HAN GR, Jiang HX, Wang CM, Ding Y, et al
Long-term safety and efficacy of telbivudine in infants born to mothers treated during the second or third trimesters of pregnancy.
J Viral Hepat. 2017;24:514-521.
PubMed Abstract available

May 2017

BROUWER WP, van der Meer AJ, Boonstra A, Plompen EPC, et al
Prediction of long-term clinical outcome in a diverse chronic hepatitis b population: role of the PAGE-B score.
J Viral Hepat. 2017 May 24. doi: 10.1111/jvh.12727.
PubMed Abstract available

FITCH DN, Dharod A, Campos CL, Nunez M, et al
Use of Electronic Health Record Clinical Decision Support Tool for HCV Birth Cohort Screening.
J Viral Hepat. 2017 May 24. doi: 10.1111/jvh.12729.
PubMed Abstract available

ROB B, Moreno C, Van Vlierberghe H, Bourgeois S, et al
The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C infected patients treated with direct acting antivirals with and without Pegylated Interferon: A Belgian experience.
J Viral Hepat. 2017 May 15. doi: 10.1111/jvh.12726.
PubMed Abstract available

OSIBOGUN O, Ogunmoroti O, Michos ED, Spatz ES, et al
HIV/HCV Co-infection and the risk of Cardiovascular Disease: A Meta-analysis.
J Viral Hepat. 2017 May 14. doi: 10.1111/jvh.12725.
PubMed Abstract available

MCLEOD A, Cullen BL, Hutchinson SJ, Roy KM, et al
Limited Impact of Awareness-Raising Campaigns on Hepatitis C Testing Practices among General Practitioners.
J Viral Hepat. 2017 May 14. doi: 10.1111/jvh.12724.
PubMed Abstract available

KIM GA, Han S, Kim HD, An J, et al
Higher Risk of Hepatocellular Carcinoma in Chronic Hepatitis B vs Chronic Hepatitis C after Achievement of Virologic Response.
J Viral Hepat. 2017 May 12. doi: 10.1111/jvh.12723.
PubMed Abstract available

WEDEMEYER H, Craxi A, Zuckerman E, Dieterich D, et al
Real-World Effectiveness of Ombitasvir/Paritaprevir/Ritonavir +/- Dasabuvir +/- Ribavirin in Patients with HCV Genotype 1 or 4 Infection: a Meta-Analysis.
J Viral Hepat. 2017 May 8. doi: 10.1111/jvh.12722.
PubMed Abstract available

SHAWA IT, Felmlee DJ, Hegazy D, Sheridan DA, et al
Exploration of potential mechanisms of HCV resistance in exposed uninfected intravenous drug users.
J Viral Hepat. 2017 May 5. doi: 10.1111/jvh.12720.
PubMed Abstract available

HLAING NKT, Mitrani RA, Aung ST, Phyo WW, et al
Safety and Efficacy of Sofosbuvir-Based DAA Regimens for Hepatitis C Virus Genotypes 1 - 4 and 6 in Myanmar: Real-world experience.
J Viral Hepat. 2017 May 5. doi: 10.1111/jvh.12721.
PubMed Abstract available

GANE E, Nahass R, Luketic V, Asante-Appiah E, et al
Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naive, non-cirrhotic HCV genotype 3-infected patients.
J Viral Hepat. 2017 May 4. doi: 10.1111/jvh.12719.
PubMed Abstract available

April 2017

STEININGER K, Boyd A, Dupke S, Krznaric I, et al
HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
J Viral Hepat. 2017 Apr 25. doi: 10.1111/jvh.12707.
PubMed Abstract available

LAARIBI AB, Bortolotti D, Hannachi N, Mehri A, et al
Increased levels of soluble HLA-G molecules in Tunisian patients with chronic hepatitis B infection.
J Viral Hepat. 2017 Apr 21. doi: 10.1111/jvh.12718.
PubMed Abstract available

CAI YJ, Dong JJ, Wang XD, Huang SS, et al
A diagnostic algorithm for assessment of liver fibrosis by liver stiffness measurement in patients with chronic hepatitis B.
J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12715.
PubMed Abstract available

PAPASAVVAS E, Azzoni L, Yin X, Liu Q, et al
HCV viremia associates with NK cell activation and dysfunction in anti retroviral HIV/HCV co-infected subjects.
J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12714.
PubMed Abstract available

DE GROEN RA, Groothuismink ZMA, van Oord G, Kootstra NA, et al
NK cells in self-limited HCV infection exhibit a more extensively differentiated, but not memory-like, repertoire.
J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12716.
PubMed Abstract available

MGAIETH S, Kemp W, Gow P, Fink M, et al
Impact of viral hepatitis etiology on survival outcomes in hepatocellular carcinoma: a large multi-center cohort study.
J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12717.
PubMed Abstract available

HUANG CE, Yang YH, Chen YY, Chang JJ, et al
The impact of hepatitis B virus infection and vaccination on the development of non-Hodgkin lymphoma.
J Viral Hepat. 2017 Apr 4. doi: 10.1111/jvh.12713.
PubMed Abstract available

March 2017

VUKOTIC R, Conti F, Fagiuoli S, Morelli MC, et al
Long-term outcomes of DAAs in post-transplant advanced HCV recurrence and fibrosing cholestatic hepatitis.
J Viral Hepat. 2017 Mar 28. doi: 10.1111/jvh.12712.
PubMed Abstract available

BOGLIONE L, Mornese Pinna S, De Nicolo A, Cusato J, et al
Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study.
J Viral Hepat. 2017 Mar 26. doi: 10.1111/jvh.12711.
PubMed Abstract available

XU JH, Wang S, Xu ZN, Yu YY, et al
Entecavir maleate versus entecavir in Chinese chronic hepatitis B predominantly genotype B or C: results at week 144.
J Viral Hepat. 2017 Mar 26. doi: 10.1111/jvh.12710.
PubMed Abstract available

SU H, Shao Z, Pu Z, Wang Y, et al
Overt and occult hepatitis B virus infection among community children in Northwest China.
J Viral Hepat. 2017 Mar 25. doi: 10.1111/jvh.12709.
PubMed Abstract available

WELZEL TM, Hinrichsen H, Sarrazin C, Buggisch P, et al
Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.
J Viral Hepat. 2017 Mar 25. doi: 10.1111/jvh.12708.
PubMed Abstract available

January 2017

VUKOTIC R, Di Donato R, Conti F, Scuteri A, et al
Secondary prophylaxis of hepatocellular carcinoma: the comparison of direct-acting antivirals with pegylated interferon and untreated cohort.
J Viral Hepat. 2017;24:13-16.
PubMed Abstract available

LI X, Gou C, Yao L, Lei Z, et al
Patients with HBV-related acute-on-chronic liver failure have increased concentrations of extracellular histones aggravating cellular damage and systemic inflammation.
J Viral Hepat. 2017;24:59-67.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: